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ABSTRACT 
Peripheral proteins from mammals often exhibit multi-domain structures and 
require metal ions such as calcium as co-factors. This dissertation investigates two types 
of such proteins — pulmonary collectins (surfactant proteins A and D) and 
phosphatidylinositol-specific phospholipase C (PLC) 1 — and their interactions with 
model membranes. One approach to work around the complexity brought upon by such 
multi-domain protein structure is to use a truncated construct or an isolated single domain. 
For pulmonary collectins, homotrimers consisting of the neck domain and the 
carbohydrate recognition domain were used in a novel NMR assay for better 
understanding of their lipid-specific interactions with the membranes. For PLC 1, we 
were particularly interested in the role of the EF-hand domain. The isolated EF-hand 
domain of PLC 1 was first used to characterize its interactions with membranes and 
identify key residues responsible for such interactions. These key residues in the 
N-terminal lobe of the EF-hand domain, either cationic or hydrophobic, were then found 
to affect the hydrolysis activity of the full-length enzyme. A common role for this region 
of the PLC in facilitating proper membrane association was thus proposed. 
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Chapter 1 Introduction 
1.1 Membrane lipids and model membranes 
Phospholipids are lipids containing one or more phosphate groups, particularly 
those derived from either glycerol or sphingosine. They are very important for the 
structure and function of cell membranes and are the most abundant components of 
membranes (1), which also contain cholesterol and small amounts of glycolipids (2). 
Phospholipids vary in types of head group, acyl chain lengths and chain saturation states 
(Fig. 1-1). Biological membranes of different types of cells or subcellular organelles are 
composed of varying types of lipids, and the lipid compositions are correlated to the 
processes occurring across the membrane and regulated by lipid metabolism and 
transport. Predominant lipid components such as phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and phosphatidylglycerol (PG), sphingomyelin, and 
cholesterol mainly serve as building blocks for the membrane barriers that segregate cells 
and subcellular organelles from their respective environments, whereas lipids of low 
abundance, phosphatidic acid (PA) and phosphoinositides (PIPx) for example, function as 
signaling molecules. 
Lipid molecules cluster together due to their hydrophobic properties, and in 
biological systems their flexibility allows them to adapt to the shape of surrounding 
proteins. In protein-membrane interaction studies, artificial membranes are frequently 
used as a model for these complex biological membranes. Currently, several aggregates 
used as models for membranes are available for different purposes (Fig. 1-2) (3). The 
most popular membrane system used for biochemical assays is the liposome or vesicle 
2 
 
which provides a closed, stable and regular bilayer structure (4). The diameter typically 
ranges from 15–50 nm (for small unilamellar vesicles [SUVs]); up to 100–1000 nm (for 
large unilamellar vesicles [LUVs]). I have used both SUVs and LUVs extensively in my 
studies. Alternatively, depending on the biophysical techniques used for the model 
membrane study, systems like lipid monolayers at the air-water interfaces, black lipid 
membranes (BLMs), solid-supported (or immobilized) lipid monolayers and bilayers and 
giant unilamellar vesicles (GUVs) are also used (4,5). 
One of the most important properties of lipid bilayers is their fluidity. The 
biologically most relevant membrane phase is the liquid-crystalline phase (Fig. 1-3A) (6), 
occurring above the melting point (Tm). It is characterized both by low conformational 
order in the hydrocarbon chains (lower internal order) and by low translational order (low 
packing order, high translational diffusion).  In contrast, below Tm, the bilayers exist in 
the gel phase (Fig. 1-3B), which is characterized by a highly ordered configuration of the 
hydrocarbon chains and impeded lateral movement (4). The fluidity of the membrane is 
dependent on the temperature and lipid composition (lipid chain length, presence and 
position of double bonds, and in particular, the presence of cholesterol). In my study on 
the interaction of lung collectins with lipid ligands in Chapter 3, I have made great efforts 
to maintain the fluidity of the membranes. 
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Figure 1-1. General phospholipid structure. 
 
Lipid name R 
Net charge at 
physiological pH 
Phosphatidic Acid (PA) —H −2 
Phosphatidylmethanol (PMe) —CH3 −1 
Phosphatidylserine (PS) —CH2CH(COO
−) NH3
+ −1 
Phosphatidylglycerol (PG) —CH2CH(OH)CH2OH −1 
Phosphatidylinositol (PI) 
 
 
−1 
Phosphatidylethanolamine (PE) —CH2CH2NH3
+ 0 
Phosphatidylcholine (PC) —CH2CH2N(CH3)3
+ 0 
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Figure 1-2. Lipid aggregates and model membranes. 
 
 
Figure 1-3. Schematic views of different bilayer phases. (A) The liquid-crystalline phase; 
(B) the gel phase. (Figures adapted from reference 4.) 
 
 
B A 
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1.2 Membrane binding assays for peripheral proteins 
In contrast to constitutive membrane proteins with transmembrane insertion, 
many signaling proteins such as phospholipases, protein kinases C, lipid kinases and lipid 
phosphatases translocate to cellular membranes only under certain circumstances (e.g. 
upon stimulation by upstream protein effectors, lipid second messengers, or calcium). 
The cellular activities of these peripheral proteins are dependent on their membrane 
binding affinities. Therefore choosing an appropriate membrane binding assay is essential 
for understanding their function and regulation. Membrane affinity of peripheral proteins 
can be measured either by direct assays that continuously monitor membrane-protein 
interaction or by separation assays that physically separate and quantify membrane-bound 
and free protein (5).  
1.2.1 Direct assays 
Fluorescence spectroscopy is one of the most commonly used and versatile tools 
for measuring membrane-protein binding. The intrinsic fluorescence method utilizes the 
sensitivity of tryptophan (or tyrosine) residues of the protein to changes in the polarity, 
dielectric constant or polarizability of its micro-environment. For example, in a 
hydrophobic environment, the tryptophan fluorescence generally shifts to a shorter 
wavelength (blue shift). The change in intrinsic tryptophan fluorescence can reflect the 
interaction of protein with the membrane and/or the conformational changes induced by 
membrane binding. This method does not require modification of the protein or the lipids. 
However, the protein must either have a tryptophan residue near the membrane binding 
surface or have one introduced genetically; the presence of multiple tryptophan residues 
could complicate matters as well, if they are affected differently and cancel each other 
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out. A more sensitive fluorescence method is fluorescence resonance energy transfer 
(FRET). FRET can measure the distance between the donor and the acceptor, as long as 
they are within the Förster distance (10–75Ǻ, depending on the donor-acceptor pair) (5). 
Therefore, this technique not only measures the affinity of peripheral proteins for the 
membranes, but also provides information about their membrane binding geometry. For 
both intrinsic fluorescence and FRET methods, when high concentrations of lipids are 
used, the signal must be corrected due to enhanced light scattering, which could 
complicate assay results. I have used both of these methods in my studies on the 
interaction of the isolated EF-hand domain of PLC 1 with model membranes in Chapter 
4. Fluorescence correlation spectroscopy (FCS) is another fluorescence technique that is 
based on the time correlation of temporal fluctuations of fluorescence detected in the 
focal volume. It reflects dynamic parameters of a system at equilibrium (4). This method 
can reach single-molecule sensitivity, employing very small amounts of the protein and 
the lipids. However, a fluorescence label must be introduced to the protein, and the 
instrumentation needed for FCS is expensive. 
Surface plasmon resonance (SPR) has gained enormous popularity in recent 
decades. By measuring changes in the refractive index on a metal (e.g. gold) surface, SPR 
can monitor the surface adsorption of biomolecules in real time. Lipid bilayers can be 
immobilized on the sensor metal surface in such ways as attaching biotinylated lipid 
vesicles to streptavidin-derivatized sensor surface (7,8), or using a commercial L1 sensor 
chip with hydrophobic anchors (Biacore) (9). It should be noted that the dissociation 
constant (Kd) obtained by SPR is expressed in terms of molarity of protein binding sites 
on the membrane but not in lipid concentration because it is difficult to determine an 
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accurate lipid concentration on the sensor chip (5). While SPR allows rapid and direct 
determination of membrane association and dissociation rate constants with high 
sensitivity, the kinetic SPR data can be quite complex and thus require careful analysis. 
Additionally, SPR instrumentation is also quite expensive. 
Isothermal titration calorimetry can accurately determine Kd, stoichiometry, and 
thermodynamic parameters by monitoring the heat change during a binding process (5). 
The binding it measures is under true equilibrium conditions without sample modification 
and immobilization, but the assay requires relatively large amounts of samples. 
Lipid monolayers, in combination with the measurement of surface tension or 
more recent techniques such as infrared reflection-absorption spectroscopy (10), uniquely 
provide information about the penetration of peripheral proteins into the membrane. 
1.2.2 Separation assays 
Centrifugation is the most frequently used separation method for 
membrane-bound and free proteins because of its simplicity. To achieve efficient 
separation, high-speed centrifugation is needed. Alternatively, vesicles are loaded with 
high-density substance such as sucrose (11) or dextran (12) to facilitate sedimentation. A 
filter membrane with specific exclusion size can be used for separation as well. After the 
separation, the membrane-bound and free proteins can be quantified by radioactivity 
measurement (for radiolabeled protein), protein assay (usually a colorimetric assay), gel 
electrophoresis followed by staining and density measurement, or enzyme activity assay 
if the protein is an enzyme. One of the drawbacks of this method is the concern over the 
perturbation of the equilibrium between bound and free proteins due to extended 
centrifugation. Gel filtration is another separation method that relies on the large size 
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difference between lipid vesicles and proteins. However it is not as sensitive as the other 
assays mentioned. Alternatively, affinity chromatography using protein or lipids 
immobilized on a short column has shown its potential as a membrane affinity assay (13). 
In my study, centrifugation separation combined with a colorimetric assay for 
quantification of protein has been extensively used, often in parallel with other binding 
methods for validation. 
 
1.3 Lung surfactant 
Lung surfactant is a complex mixture of lipids and proteins that covers the large 
surface area of the alveolar epithelium. Consisting of over 90% lipids (with 
dipalmitoylphosphatidylcholine (DPPC) as the major constituent) and 5–10% proteins 
(with surfactant protein A, B, C, D as the major constituents), lung surfactant reduces 
surface tension at the air/water interface of the alveoli, making the absorption of air (O2, 
N2, CO2) easier and preventing alveolar collapse during exhalation (14). In addition, 
surfactant proteins play diverse and important roles in host defense (15) and surfactant 
homeostasis (16). Surfactant is synthesized by alveolar type II cells and stored as 
intracellular inclusion organelles called “lamellar bodies”. It is subsequently secreted into 
the alveolar space where it forms a lattice called “tubular myelin”, which is believed to be 
the precursor of the monolayer lipid film covering the alveolar space (17,18). 
Two of the major surfactant proteins (SP), SP-A (35 kDa) (the most abundant 
surfactant protein in lung) and SP-D (43 kDa), are members of the collectin family. 
Compared to the other two surfactant proteins, SP-B (14 kDa) and SP-C (6 kDa), which 
are small, extremely hydrophobic proteins, SP-A and SP-D are large hydrophilic proteins. 
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They share the same primary structure with the other collectin family members such as 
mannose binding protein (19), which consists of four segments: 1) a cysteine-containing 
N-terminal segment, 2) a collagen-like domain composed of Gly-Xaa-Yaa repeats, 3) the 
-helical neck region, and 4) the calcium-dependent C-terminal carbohydrate recognition 
domain (CRD) (20). Collectin monomers assemble into homotrimers through the 
formation of a triple coiled-coil structure in the neck domain and a triple helix in the 
collagen-like domain. These trimeric subunits, the basic functional units, are 
subsequently assembled into higher oligomeric forms via intermolecular disulfide bond 
formation in the N-terminus. For example, SP-D almost exclusively assembles as 
dodecamers (4 trimers), although trimers and higher-order multimers of SP-D have also 
been observed (21). SP-A, on the other hand, assembles as octadecamers (6 trimers) (22) 
(23). The SP-A octadecamers adopt a tulip bouquet shape due to a kink in the 
collagen-like domain, whereas the SP-D dodecamers take the shape of a cross (Fig. 1-4). 
The oligomerization of SP-A and SP-D is important for their roles in pathogen 
recognition and clearance (24,25), as well as in the maintenance of lipid ultrastructures 
and other lipid-related interactions (26). SP-A, for example, is critical for the formation 
of tubular myelin, while SP-D is involved in the formation of atypical hexagonal tubules 
(27). 
As pattern recognition molecules, SP-A and SP-D recognize broad yet different 
patterns. These ligands include simple carbohydrate molecules as well as carbohydrate 
moieties commonly found on the surface of bacteria, fungi, viruses and yeast. For 
example, while both proteins bind to mannose and glucose, SP-A preferentially binds to 
L-fucose (28) and SP-D preferentially binds to inositol and maltose (29). Likewise, both 
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proteins bind to bacterial lipopolysaccharide (LPS). SP-A preferentially interacts with the 
lipid A domain of LPS (30), whereas SP-D binds to the core oligosaccharide domain 
(31,32). In addition, SP-A and SP-D also bind to membrane lipids. SP-D preferentially 
binds to phosphatidylinositol (PI) (33,34) as well as glucosylceramide, both of which are 
minor components of surfactant. SP-A, on the other hand, binds to DPPC (35), the major 
lipid component in lung surfactant. Moreover, lung collectins have also been shown to 
bind to other host proteins (36). The crystallographic studies of SP-A (37,38) and SP-D 
(10,20,32,39–44) have provided many insights on the structural requirements for calcium 
and ligand binding (Fig 1-5). Binding sites for calcium and sugars have been identified in 
each of the two proteins, which can explain at least some of their differences in ligand 
specificities and functional roles. For SP-D, the two loops at the lectin site are in a highly 
stable conformation through multiple interrelated interactions of the structural calcium 
sites (38,39). For SP-A, the two loops lack aspartate and glutamate side chains to bind 
non-lectin calcium ions, resulting in a more flexible lectin site, which undergoes a 
significant conformational change upon ligand binding (38). While both proteins can 
interact with sugars and other polyols in a calcium-dependent fashion, they display 
significant differences in the spatial orientation, charge, and hydrophobicity of their 
binding surfaces (45). Consequently, SP-D appears particularly adapted to interactions 
with complex carbohydrates and anionic phospholipids such as PI. In contrast, SP-A 
shows features consistent with its preference for lipid ligands, including lipid A and the 
major surfactant phospholipid, DPPC. Compared to the interactions with carbohydrates, 
the modes of interaction of SP-A and SP-D with surfactant lipids are generally less well 
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understood. My studies have focused on the lipid-specific interactions of these two 
proteins with model membranes. 
 
Figure 1-4. Schematic representation of the oligomerization of the pulmonary collectins 
(figure adapted from reference 25). 
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Figure 1-5. Crystal structures of (A) SP-A (neck + CRD) complexed with Ca2+ and 
glycerol (PDB ID: 3PBF) and (B) SP-D (neck + CRD) homotrimer complexed with Ca2+ 
and I-1-P (PDB ID: 3IKP). SP-A is shown in magenta. The three monomers of SP-D in 
the homotrimer are shown in red, blue and white, respectively. Calcium ions are shown 
as green spheres. Glycerol and I-1-P, respective ligand analogs of SP-A and SP-D, are 
shown as sticks. 
 
 
 
A 
B 
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1.4 Mammalian phosphoinositide-specific phospholipase C 
Phosphoinositide-specific phospholipase C (PLC) enzymes are common effectors 
in the cellular signal transduction process. All PLC members are multi-domain proteins 
regulated by a broad spectrum of modulators, including heterotrimeric G protein subunits, 
monomeric GTPases from Rho and Ras families, receptor and no-receptor tyrosine 
kinases and lipid components of cellular membranes. 
The first evidence of phospholipase C (PLC) activity in cells was reported by 
Hokin et al. in 1953 (46) who observed specific hydrolysis of the phospholipids in pigeon 
pancreas slices after cholinergic stimulation. In the following twenty-some years, 
mammalian PLC was recognized as a key enzyme in phosphoinositide metabolism that 
hydrolyzed phosphoinositide to the corresponding inositol phosphate and diacylglycerol 
(DAG) upon stimulation (47–54). In 1983, Streb et al. (55) described the intracellular 
calcium store release as triggered by inositol-1,4,5-trisphosphate (IP3), establishing a 
direct link between PLC and calcium mobilization. Meanwhile, DAG, the other product 
of PLC hydrolysis, was found to activate protein kinase C by increasing its affinity for 
calcium (56,57), thereby establishing PLC as an essential component in this bifurcated 
signaling pathway. The 1980s also saw reports of purification and characterization of 
PLC isozymes of different molecular masses and isoelectric points from several tissues of 
species such as rat, sheep, guinea pig, bovine and human (58–64), leading to the 
publication by Rhee et al. in 1989 (65) proposing a unified nomenclature using Greek 
letters. The PLC isozymes were categorized into immunologically distinct subtypes , , 
and  (PLC  was later found to be a protein isomerase without phospholipase activity 
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(66)). This nomenclature has since been used and expanded as more PLC isozymes are 
discovered.  
To date, 13 distinct isoforms of PLC have been identified and cloned, classified 
into six subfamilies based on sequence homology: 1, 2 (67), 3, 4, 1, 2 (68), 1, 
3,4 (69), –,  (73), 1 (74), and 2 (75,76). While these subfamilies share a 
conserved core architecture and a common catalytic mechanism (77), they differ in 
structural organization, mode of regulation and biological function.  
The core conserved regions of most PLC isoforms contain (from N-terminus to 
C-terminus) a pleckstrin homology (PH) domain, EF-hand domain, a catalytic TIM barrel 
divided into two halves (X and Y), and a C2 domain (Fig. 1-6). The catalytic domain is 
the most conserved in the core structure both structurally and functionally (78). The rest 
of the domains within the core unit exhibit well conserved general folds, but they may 
bind to different ligands. For example, it is well documented that the PH domain of 
PLC 1 binds to phosphatidylinositol 4,5-bisphosphate (PIP2) with high affinity and 
specificity (79,80), whereas the PH domain of PLC  has been found to bind to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) (81). On the other hand, the PH domain of 
PLC isozymes lacks the necessary residues and electrostatic potentials to bind 
phosphoinositides (82). Instead, the PH domain of PLC 2 directly interacts with Rac1 
from the Rho-family GTPases (82) and the G subunit of heterotrimeric G protein 
(83,84). The crystal structures of PLC 1 (85,86), 2 (82,87) and 3 (88) reveal that there 
are conserved, extensive inter-domain interactions between the EF-hand, catalytic and C2 
domains. It is predicted that these three domains will be structurally highly similar in all 
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PLCs with the N-terminal PH domain attached either loosely (as in PLC 1) or making 
contacts with the other domains (as in PLC 2 and 3) (78). PLC  (along with PLC from 
plants) does not have this PH domain. 
With the exception of PLC and , PLC isoforms (  all have structural 
domains unique to their own subfamilies (Fig. 1-1), which are linked to their modes of 
regulation. PLC  isozymes are distinguished by an elongated C-terminal tail of ~400 
residues, which contains sequences important to membrane binding, nuclear localization 
and the activation by G protein subunits of the enzymes (89). The isoforms in this 
subfamily have been well characterized for their activation by G protein-coupled 
receptors (GPCR). Importantly, activated PLC s subsequently deactivate their upstream 
effector heterotrimeric G proteins, suggesting a dynamic catch-and-release mechanism 
for sharpened spatiotemporal signals (88). In PLC , a unique array of domains, termed 
the PLC-specific array (-SA), is inserted between the catalytic X and Y domains. -SA 
consists of a split PH domain flanking two tandem SH2 domains (nSH2 and cSH2) and 
one SH3 domain (90). This region has been implicated in the activation of PLC 
isozymes by receptors with intrinsic or associated tyrosine kinase activity. In particular, 
the SH2 domains of PLC 1 mediate binding to autophosphorylated tyrosine residues 
within the intracellular region of receptor tyrosine kinases (RTKs) such as the epidermal 
growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) (91). 
Tyrosine residues that can be phosphorylated (which leads to PLC activation) also reside 
in -SA (92,93). PLC  contains a cell division control 25 (CDC25) guanine-nucleotide 
exchange factor (GEF) domain at the N-terminus, as well as two ubiquitin-like folds at 
the C-terminus (94). The former is predicted to function as an upstream activator of small 
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GTPases; whereas the latter, initially designated as RA1 and RA2 domains because of 
their predicted Ras-associating property, can only bind Ras GTPases via the RA2 domain 
(95), giving PLC  the unique property (among PLC subfamilies) of direct regulation by 
small GTPases from the Ras family. In addition, PLC can be stimulated by subunits of 
heterotrimeric G proteins and small GTPases from the Rho family, suggesting a 
complexity and possible interplay between the regulatory networks (78). PLC  isozymes 
contain an extended C-terminus with a PDZ-binding motif (76). PLC 1 and 2 have 
been reported to participate in GPCR-mediated activation (76,96). 
Compared to PLC and  isozymes, reports of regulatory proteins for PLC 1 
have been sparse. Proteins that have been suggested for PLC 1 activation include a 
GTPase activating protein for the Rho family (RhoGAP) (97), a GTP-binding protein 
transglutaminase II (98), the small GTPase Ral and calmodulin (99). Regulation of 
PLC 1 via (de)phosphorylation has also been reported (100). How PLC  function is 
regulated remains unclear, although it has been suggested that PLC  can be active in 
cells in a resting state since it has an exceptionally high sensitivity to calcium 
(EC50=52 nM) (101). 
Serving as an effector for upstream receptors for hormones, neurotransmitters, 
antigens and growth factors, as well as a catalyst for the generation of second messengers 
IP3 and DAG, PLCs contribute to the regulation of biological functions as diverse as cell 
motility, fertilization and sensory transduction (physiological roles for each isozyme are 
reviewed in reference 90). 
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Figure 1-6. Domain organization of PLC subfamilies highlighting their common and 
unique features. The core conserved regions consist of the PH domain (cyan), the 
EF-hand domain (magenta), the catalytic X/Y domain (yellow), and the C2 domain 
(green), with the exception of PLC , which lacks the PH domain. The unique regions 
include: in PLC  and PLC  there is a C-terminal tail (blue); in PLC , there is an array 
of domains inserted between the catalytic X and Y domains, namely the PLC-specific 
array (-SA) comprising a “split” PH domain (spPH), two SH2 domains (dark grey) and 
one SH3 domain (light grey); in PLC , there is a CDC25 domain (pink) at the 
N-terminus and two Ras-association (RA) domains (purple) at the C-terminus. 
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1.5 Thesis directions 
The aim of this dissertation is to understand on a molecular level the membrane 
association mechanism of two types of calcium-dependent, multi-domain mammalian 
peripheral proteins, namely the pulmonary collectins and the phosphoinositide-specific 
phospholipase C 1, and how the interactions with membranes dictate the functions of 
these proteins. 
The first part of my work is to investigate the lipid-specific interactions of 
pulmonary collectins (SP-A and SP-D) with model membranes. Although the 
crystallographic studies of these two proteins have provided many insights on the 
structural requirements for calcium and ligand binding, the modes of their interactions 
with surfactant lipids are not well understood. Parallel to these structural studies, I have 
developed an NMR assay to monitor the interactions of SP-A or SP-D with their 
respective lipid ligands. This novel assay requires relatively simple operations to control 
the phase of the lipid aggregates and distinguish a specific lipid in lipid mixtures. 
Combined with techniques such as vesicle leakage assay and negative staining 
transmission electron microscopy, my work contributes to the understanding of lung 
collectin/lipid interactions, supporting the view that SP-A and SP-D play complementary 
roles in innate immune response and lung surfactant homeostasis. In addition, the 
1H NMR assay utilizing mixed vesicles of proteo/deuterated lipids developed in this 
study can be extended to other membrane-associated proteins. 
The second part of my work focuses on the EF-hand domain in mammalian PLC. 
While many structural features of the PLCs and their contributions to the enzyme 
function have been elucidated, the role of the EF-hand domain (which is present in all 
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PLC isozymes and required for protein activity) remains unclear. To tackle this question, 
I first used the isolated EF-hand domain of PLC 1 to characterize its interactions with 
membranes. Using several biophysical methods including intrinsic tryptophan 
fluorescence, fluorescence resonance energy transfer, centrifugation-filtration, and NMR 
spectroscopy, I found that this isolated domain binds to membranes containing anionic 
phospholipids. Subsequently, using site-directed mutagenesis, I identified several 
residues in this domain, either cationic or hydrophobic, that contribute to the affinity for 
the interfacial surface. To further examine the role of the key residues in the EF-hand 
domain in the enzyme activity, I constructed two mutants of the full-length PLC 1, a 
single mutant W144A and a double mutant R150A/K151A, and found that these 
mutations compromised enzymatic activity. Finally I propose that a common role for the 
N-terminal lobe of the EF-domain of PLCs is to facilitate proper membrane association.  
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Chapter 2 Materials and Methods 
2.1 Materials 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl(d62)-sn-
glycero-3-phosphocholine-1,1,2,2-d4-N,N,N-trimethyl-d9 (d75-DPPC), 1,2-diheptanoyl-
sn-glycero-3-phosphocholine (diC7PC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine 
(POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPA), 1,2-dioleoyl-sn-glycero-
3-phosphate (DOPA), 1,2-dioleoyl-sn-glycero-3-phosphoethanol (DOPMe), 1,2-dioleoyl-
sn-glycero-3-[phospho-rac-(1-glycerol)] (DOPG), 1,2-dioleoyl-sn-glycero-3-phospho-L-
serine (DOPS), L-α-phosphatidylinositol (bovine liver) (PI), L-α-phosphatidylinositol-
4,5-bisphosphate (porcine brain) (PIP2), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-(5-dimethylamino-1-naphthalenesulfonyl) (dansyl-PE) and sphingomyelin (porcine 
brain) were purchased from Avanti Polar Lipids, Inc., and used without further 
purification.  
Cholesterol, thrombin, Triton X-100, and D-glucose-6-phosphate (G6P) were 
purchased from Sigma-Aldrich Chemical Co. Chloroamphenicol, ampicillin and IPTG 
were purchased from American Bioanalytical Inc. Chloroform-D (CDCl3) and 
methanol-D4 (CD3OD) were purchased from Cambridge Isotope Laboratories, Inc. 
6-Carboxyfluorescein was purchased from Eastman Kodak Company. (1-Oxyl-2,2,5,5-
tetramethyl-3-pyrroline-3-methyl) methanethiosulfonate (MTSL) was purchased from 
Toronto Research Chemicals Inc. 
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2.2 Methods 
2.2.1 Construction of PLC 1 mutants 
A plasmid containing the rat PLC 1 gene was a gift from Dr. Matilda Katan at 
the Cancer Research UK Centre for Cell and Molecular Biology, Chester Beatty 
Laboratories, the Institute of Cancer Research, London, U.K (102). A plasmid containing 
the human PLC 1 EF-hand domain gene was a gift from Dr. Jon W. Lomasney at the 
Feinberg Cardiovascular Research Institute, Departments of Pathology and 
Pharmacology, Northwestern University Medical School, Chicago, Illinois, USA (103). 
The full-length PLC 1 and the isolated EF-hand genes were inserted into the pGEX-2T 
vector with an N-terminal glutathione S-transferase (GST) tag. All mutations of the PLC 
genes were carried out by QuikChange methodology, using the site-directed mutagenesis 
kit from Agilent Technologies and following the instruction manual provided by the 
manufacturer (104). The mutagenic primers were designed following the guidelines 
provided by Agilent Technologies (104) and purchased from Eurofins MWG Operon. 
The sequences of all the primers used are listed in Table 2-1. Briefly, to a reaction 
mixture comprising 5 l of 10x reaction buffer, 10 ng of plasmid containing the rat PLC 
1 gene or the human PLC 1 EF-hand domain gene, 125 ng of each of the 
complementary mutagenic primers, 1 l of dNTP mix, and ddH2O that made up to a final 
volume of 50 l, 1 l of PfuTurbo DNA polymerase was added. The mixture was then 
subjected to thermal cycles (cycling parameters listed in Table 2-2) to allow DNA 
replication. Following temperature cycling, the product was treated with 1 l of the Dpn I 
restriction enzyme at 37oC for 1 h to digest the parental plasmid. The DNA treated with 
Dpn I was transformed into XL1-Blue supercompetent cells by heat shock, spread on 
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LB-ampicillin agar plates and incubated at 37oC for >16 h. One colony picked from the 
agar plates was inoculated into 5 ml LB media and incubated with shaking overnight at 
37oC in the presence of 100 g/ml ampicillin. The cell culture was centrifuged, and the 
DNA was purified from the cell pellet using QIAprep Spin MiniPrep Kit from Qiagen 
(following the microcentrifuge protocol in the provided handbook (105)). The DNA 
products were sequenced by Genewiz to confirm successful mutations. 
 
Table 2-1. List of mutagenic primers (reverse primers not listed) corresponding to 
site-specific mutagenesis of PLC. The mutations are indicated in bold. 
Mutant Forward primers (from 5’ to 3’) 
W144A cag aag cta cag cac gcg att cac tcc tgc ttg c 
W144A/I145A g aag cta cag cac gcg gct cac tcc tgc ttg cg 
W144A/R150A/K151A g aag cta cag cac gcg att cac tcc tgc ttg gc 
C148S g cac tgg att cac tcc agc ttg cga aaa gc 
L149A g cac tgg att cac tcc tgc gcg cga aaa gct gac 
R150A/K151A g cac tgg att cac tcc tgc ttg gca gca gct gac aaa aac aag g 
R150A/K151A/K154A gc ttg gca gca gct gac gca aac aag gac aac aag 
R150A/K151A/K154A/K156A g gca gca gct gac gca aac gcg gac aac aag atg ag 
F162A g gac aac aag atg agc gcc aag gag ctg cag aac 
K163A g atg agc ttc gcg gag ctg cag aac ttc ctg 
F168A c aag gag ctg cag aac gcc ctg aag gag ctc aac 
K170A g cag aac ttc ctg gcg gag ctc aac atc cag g 
V176A ag ctc aac atc cag gcg gac gac agc tat gc 
Y180A c cag gtg gac gac agc gct gcc cgg aag atc ttc 
R182A g gac gac agc tat gcc gcg aag atc ttc agg gag 
R182A/K183A c gac agc tat gcc gcg gcg atc ttc agg gag tgt 
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R182A/R186A gcc gcg aag atc ttc gcg gag tgt gac cac tc 
R182A/K183A/R186A c gac agc tat gcc gcg gcg atc ttc gcg gag tgt 
K183A c gac agc tat gcc cgg gcg atc ttc agg gag tgt 
K183A/R186A gcc cgg gcg atc ttc gcg gag tgt gac cac tc 
F185A c tat gcc cgg aag atc gcc agg gag tgt gac cac 
R186A gcc cgg aag atc ttc gcg gag tgt gac cac tc 
C188S g aag atc ttc agg gag agt gac cac tcc cag ac 
I201A c ctg gag gac gag gag gct gag gcc ttc tac aag 
 
Table 2-2. Cycling parameters for site-directed mutagenesis 
Segment Cycles Temperature Time 
1 1 95oC 1 min 
2 16 
95oC 50 sec 
60oC 50 sec 
68oC 11 min 
3 1 68oC 7 min 
 
2.2.2 Overexpression and purification of PLC proteins 
The plasmids were transformed into E. coli BL21-Codonplus (DE3)-RIL cells. 
Overexpression of the proteins followed protocols used for a bacterial PI-PLC (106). One 
colony was inoculated into 5 ml LB media and incubated with shaking overnight at 37oC 
in the presence of antibiotics (34 g/ml chloroamphenicol and 100 g/ml ampicillin). 
The cell culture was then added to 2 L LB media (with 34 g/ml chloroamphenicol and 
100 g/ml ampicillin) and incubated at 37oC with shaking. When OD600 reached ~0.8, 
IPTG was added to a final concentration of 0.8 mM, and the incubation continued for 
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another 20 h at 16oC. The cells were harvested by centrifugation at 5,000 rpm at 4oC for 
8 min. The cell pellets were either stored at −20oC for later use, or lysed immediately. 
PBS buffer (pH 7.4) was used to resuspend the cell pellet, which was then lysed 
by sonication on ice using a Branson Sonifier Cell Disrupter. Cell debris was pelleted by 
centrifugation at 15,000 rpm for 30–40 min. The supernatant with the PLC protein was 
ready for subsequent purification steps. The PLC proteins were purified by affinity 
chromatography: E. coli cell lysate was mixed with glutathione Sepharose 4B resin (GE 
Healthcare) (2 ml bed volume of resin for lysate from 2 L cell culture) and gently shaken 
for 1 h at room temperature. The resin was washed with PBS buffer to remove 
nonspecifically bound impurities. Thrombin (25 unit per 2 L cell culture) was added to 
the resin, which was then gently shaken at 4oC for ~18 h to cleave the GST tag from the 
PLC protein. The PLC protein was eluted from the resin with PBS buffer. The 
concentration of the protein was determined by the absorption at 280 nm using an 
extinction coefficient calculated by the Web-based ProtParam software (107), or by DC 
protein assay (BioRad) (108).  
 
2.2.3 Spin labeling of the EF-hand domain of PLC 1 
Mutants of the EF domain of PLC 1 mutants, C148S and C188S, were 
specifically spin labeled on the only remaining Cys (Cys188 and Cys148, respectively) 
by MTSL (chemical structure shown in Fig. 2-1A). The reaction scheme is shown in 
Fig. 2-1B. MTSL was prepared as a 20 mg/ml stock solution in acetone and stored at 
−20oC. The purified EF mutants (8–10 mg/ml stocks) stored in PBS buffer with 2 mM 
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DTT, pH 7.4, were passed through a Micro Bio-spin 6 column (Bio-Rad) equilibrated 
with PBS to remove the DTT. Approximately 5-fold MTSL over the total amount of 
protein cysteines was transferred to a microtube, and a stream of nitrogen gas was used to 
remove the acetone. The protein solution was then mixed with the MTSL and incubated 
with shaking at room temperature for 3–5 hr. The excess MTSL was removed by three 
consecutive Micro Bio-spin 6 columns equilibrated with 10 mM borate (pH 7.8) in D2O 
(for 1H NMR experiments). 
 
Figure 2-1. Spin label reaction. (A) Chemical structure of the spin label reagent MTSL; 
(B) reaction scheme for the spin label reaction. 
 
 
 
A 
B 
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DTNB assay (also called “Ellman assay”) (109) was used to monitor the 
completion of the labeling reaction as well as the removal of excess MTSL. Briefly, a 
mixture comprising 50 l of 2 mM DTNB, 20 l of 1 M Tris (pH 8), 20 l of 20% SDS,  
5–15 l of the protein or the buffer (as a control), and ddH2O that made up to a final 
volume of 200 l, was incubated at room temperature for 15 min. The absorbance of the 
mixtures was then measured at 412 nm. If all protein cysteines were successfully labeled 
and all excess MTSL was removed, the absorbance of the protein/DTNB mixture would 
be comparable to that of the buffer/DTNB mixture. 
 
2.2.4 Circular Dichroism (CD) spectroscopy of the EF-hand domain of PLC 1 
The secondary structure of the isolated EF-hand domain protein was assessed by 
CD spectroscopy using an AVIV 420 spectrometer (Biomedical, Inc.). The protein was 
diluted to 0.04 mg/ml and placed in a 10 mm cuvette. The ellipticity was measured from 
190 to 260 nm at 25oC. For Tm (the temperature at which the loss of 50% of the 
secondary structure occurs) measurement, the temperature was increased from 25oC to 
90oC (or 95oC) with a step increment of 2o and 1 min for equilibration between each scan; 
the wavelength was fixed at 222 nm. 
 
2.2.5 Preparation of vesicles 
Lipids supplied as powder were first dissolved in chloroform as stock solutions. 
Measured volumes of lipid stock solutions in chloroform were placed in glass 
scintillation vials. The chloroform was removed under a stream of nitrogen gas and left a 
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thin lipid film. The lipid film was lyophilized for at least 3 h and subsequently rehydrated 
with buffer, and was dispersed by vortexing. LUVs were prepared by at least 20 passages 
of the lipid solution through polycarbonate membranes (0.1 m pore diameter) using a 
Mini-extruder (Avanti Polar Lipids, Inc.). SUVs were prepared by intermittent probe 
sonication (20–30 sec per interval) of the lipid solution on an ice bath, using a Branson 
Sonifier Cell Disrupter, until the vesicle solution became translucent. Total sonication 
time was at least 5 min. 
 
2.2.6 Binding Assays 
2.2.6.1 SP-A and SP-D vesicle binding assayed by 1H NMR spectroscopy 
The truncated (neck and CRD domains) recombinant trimeric SP-A and SP-D 
stocks (of determined concentrations) were generously provided by Dr. Erika C. Crouch 
(Department of Pathology and Immunology, Washington University School of Medicine, 
St. Louis, Missouri) and Dr. Francis X. McCormack (Division of Pulmonary/Critical 
Care Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio). The 
proteins were stored in a solution containing 10 mM HEPES, 150 mM NaCl, and 10 mM 
CaCl2, pH 7.4. Before the NMR experiments, the SP-A or SP-D stocks were diluted with 
D2O containing 10 mM imidazole, pH 8, followed by re-concentration at 4
oC using a 
centrifugal filter device with a cellulose membrane of 10 kDa cutoff. The 
dilution-concentration cycle was repeated for three times to exchange the buffers. The 
final protein concentrations (1.0–1.4 mg/ml) were either calculated using the 
28 
 
concentration values that were originally provided and the dilution factors, or determined 
by Pierce BCA protein assay (Thermo Scientific (110)).  
For the SP-D experiments, vesicles containing DPPC and anionic phospholipid, 
with a total lipid concentration of either 1.25 or 2.50 mM, in D2O containing 20 mM 
imidazole, 0.1–2 mM EDTA, 3–9 mM CaCl2, pH 8, were prepared as described above 
(Section 2.2.4) and used immediately for NMR studies. It should be stressed that these 
vesicles were prepared in the presence of the Ca2+, so the Ca2+ was on both sides of the 
vesicles. This is because for vesicles containing anionic phospholipids, especially highly 
curved SUVs, vesicle aggregation occurred when Ca2+ was added after the vesicles had 
been formed. The presence of Ca2+ on both sides of the vesicles enhanced their stability. 
As monitored by 1H NMR linewidth, vesicles prepared in the presence of the Ca2+ were 
stable for at least one day, which was sufficient time needed for these experiments.  
For the SP-A experiments, vesicles of 0.2 mM PC (DPPC, POPC, or DMPC), in 
D2O containing 10 mM imidazole, pH 7.5, were prepared as described previously and 
used immediately for NMR studies. Calcium was added after the vesicles had been 
formed and before the titration of SP-A. The addition of calcium to PC vesicles did not 
cause any significant 1H linewidth change. 
Four to five aliquots of 40–50 l SP-A or SP-D were titrated into 500 l vesicles, 
and the 1H NMR spectra were acquired at 500 MHz on a Varian INOVA 500 
spectrometer. The 1H NMR parameters included a 8.5 s pulse width (90o), recycle time 
of 3 s, 4658 Hz sweep width, digital resolution of 0.5 Hz/point, and probe temperature of 
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37oC (except for experiments with vesicles containing only proteo-DPPC, where the 
probe temperature was set at 42oC). A water suppression pulse sequence was used.  
The linewidths of 1H resonances, assigned to different regions of the phospholipid 
molecules, were measured at half-height. The assigned phospholipid regions included the 
methylenes (1.4 ppm) and terminal methyl groups (1.0 ppm) in the acyl chains, and the 
choline trimethyl group (3.4 ppm) when proteo-PC was present. These selected regions 
were printed on A4 papers for linewidth measurements. As illustrated in Fig. 2-2, a 
smooth baseline was drawn under the peaks to be measured, from which a perpendicular 
line was drawn to connect the highest point of the peak to the baseline. The length of this 
perpendicular line was the height of the peak. At half of the peak height, a line was drawn 
paralleled to the baseline, and the length of this parallel line was defined as the linewidth 
at half-height. The length was measure in millimeter (mm) by a ruler, which was then 
converted to Hertz (Hz) based on the scale printed on the same A4 paper. The error of 
measurement was estimated to be 0.5 mm (since the minimum scale on the ruler used was 
1 mm), which was equal to ~2 Hz.  
The linewidths (1/2) were plotted against the molar ratio of the added surfactant 
protein to the proteo-lipid. The plots were fit with Eqn. 2-1 to describe the interaction of 
the SP-A or SP-D with the lipids in a quantitative fashion. An 8 mM imidazole (pH 8) 
buffer was titrated into the vesicles as a control. None of the controls showed changes in 
chemical shift or linewidth with dilution by the imidazole buffer. 
  Eqn. 2-1 
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Symbols in the equation include: 1/2, linewidth of 
1H resonance assigned to a 
specific region of the phospholipid molecule; o, initial linewidth before adding SP-A 
or SP-D; b, maximum change in linewidth; [protein], concentration of SP-A or SP-D; 
[proteo-PL], concentration of proteo-phospholipid; m, cooperativity coefficient; R0.5, the 
amount of protein/proteo-lipid ratio needed for half the maximum change in linewidth. 
R0.5 is roughly related to an apparent dissociation constant. 
 
Figure 2-2.Illustration of how to measure linewidth manually. 
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2.2.6.2 PLC 1 EF-hand vesicle binding assayed by 1H NMR spectroscopy 
Ten aliquots of 10 l EF (spin labeled Cys mutants C148S or C188S, or unlabeled 
WT, in D2O buffer) were titrated into 500 l SUV of various lipid compositions (in D2O 
buffer of 10 mM borate, pH 7.8), and the 1H NMR spectra were acquired at 600 MHz on 
a Varian VNMRS 600 spectrometer The 1H NMR parameters included a 7.75 s pulse 
width (45o), recycle time of 3 s, 9615 Hz sweep width, digital resolution of 0.24 Hz/point, 
and probe temperature of 37oC, and probe temperature of 37oC. The linewidths of 1H 
resonances, assigned to methylenes (1.4 ppm) and terminal methyl groups (1.0 ppm) in 
the acyl chains of the phospholipid molecules, were measured at half-height by using the 
“dres” command in the Varian VnmrJ software (111). The exact concentrations of the 
proteins were determined after the NMR experiments using DC protein assay (108).  
 
2.2.6.3 PLC 1 EF-hand Binding assayed by steady-state fluorescence 
EF-hand domain of PLC 1 stocks were diluted to 20 M with 20 mM Tris, 
0.1 mM EGTA, pH 7.5 to a total volume of 1 ml. Stock solutions of vesicles of 20–
60 mM were titrated into the protein solution. The total volume change was no greater 
than 10%. A FluoroLog-3 spectrofluorometer (Horiba Jobin Yvon) was used for 
detection of fluorescence emission from the single tryptophan (Trp144) in the isolated 
EF-hand domain. The fluorescence spectrum was measured from 300 to 450 nm with 
excitation at 295 nm, both excitation and emission slit widths set at 2 nm, measuring 
increment of 1 nm, integration time of 0.2 sec, and at a constant temperature of 25oC.  
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2.2.6.4 PLC 1 EF-hand Binding assayed by fluorescence resonance energy transfer 
(FRET) 
The binding of PLC 1 EF-hand domain to membranes was evaluated using the 
single tryptophan in the EF-hand domain as the donor and dansyl-labeled lipid embedded 
in the membranes as the acceptor. The dansyl fluorophore has an excitation maximum at 
346 nm, therefore is an efficient acceptor for fluorescence emission from tryptophan, 
with a resonance energy transfer distance of about 20 Ǻ (112). EF-hand domain of PLC 
1 stocks were diluted to 20 M with 20 mM Tris, 0.1 mM EGTA, 150 mM NaCl, pH 
7.5 to a total volume of 1 ml. Stock solutions of vesicles of 20–60 mM (containing 1 mol% 
dansyl-PE) were titrated into the protein solution. The total volume change was no 
greater than 10%. The fluorometer and measurement parameters were the same as 
described above. When the amount of protein is fixed, the emission intensity of the 
tryptophan (around 345 nm) decreases as the concentration of vesicles (with dansyl-PE 
embedded) increases; at the same time, the emission intensity of the dansyl fluorophore 
(around 490 nm) increases. The energy transfer efficiency can be calculated from either 
the tryptophan fluorescence quenching data or the dansyl fluorescence enhancement data. 
Here we chose to monitor the donor emission (at 345 nm) as a measure for energy 
transfer, since the acceptor can be quenched by other interactions when bound to the 
protein. The FRET efficiencies E were determined by:  
E = 1 – FD-A/FD   Eqn. 2-2 
where FD-A and FD are the fluorescence intensities of the donor in the presence and in the 
absence of the acceptor. Unlabeled vesicles were always used to subtract the scattering 
background. 
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2.2.6.5 PLC 1 EF-hand vesicle binding assayed by centrifugation-filtration 
This assay was developed based on a similar method used to measure the binding 
of Bacillus thuringiensis PI-PLC to PC vesicles (106). A series of SUV samples of 
varying concentrations (ranging from 0.025 mM to 6 mM) were mixed with a fixed 
amount of EF (14–16 M) in 20 mM Tris, 0.1 mM EGTA, pH 7.5, in the absence or 
presence of 0.15 M NaCl. The same amount of EF in the absence of vesicles served as a 
control. After 15 min of incubation at room temperature, the protein/SUV mixtures were 
applied to Amicon Ultra 0.5 ml centrifugal filters with a molecular mass cutoff of 100 
kDa (Millipore), and centrifuged at 14,000 g for 30 min. The protein bound to vesicles 
was left on the filter membrane, while free protein passed through the membrane. The 
amount of free protein was analyzed by SDS-PAGE or DC protein assay (BioRad).  
In the SDS-PAGE method, the eluent from the filters was collected and 
lyophilized overnight. The lyophilized dry solid was dissolved in 15 l of water and 20 l 
of SDS loading buffer and analyzed by SDS-PAGE (12% polyacrylamide). The gels were 
imaged by EAGLE EYE from Stratagene, and the EF intensities were quantified by 
ImageJ (113).  
In the DC protein assay method, the eluent from the filters was directly quantified 
following the standard assay protocol in the instruction manual from BioRad (108). The 
fraction of free protein (Ef/ET, where ET is the total amount of protein, obtained from the 
control incubated without vesicles) at each SUV concentration was calculated. The 
fraction of EF protein bound to vesicles, Eb/ET, was then calculated as (1 – Ef/ET). The 
apparent dissociation constant (KD) was fit with the following equation  
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  Eb/ET = fmax × [PL] / ([PL] + KD)   Eqn. 2-3 
where fmax is the maximum fraction bound.  
 
2.2.7 Vesicle leakage assay 
Vesicle leakage is assessed by using 6-carboxyfluorescein (CF). When entrapped 
in the vesicles, CF self-quenches due to its high concentration. When CF leaks out of the 
vesicles, it is dramatically diluted and emits fluorescence as a result. By measuring the 
fluorescence of the vesicle solution, we can calculate the leakage percentage. TX-100 is 
used to lyse all the vesicles to obtain a 100% leakage fluorescence measurement. 
SUVs with entrapped CF were prepared as follows. DPPC and PI (4:1 molar ratio) 
were measured from stock solutions in chloroform and dried as previously described. The 
lipid film was subsequently rehydrated with 50 mM Tris (pH 7.5), 100 mM CF and 
0.2 mM EDTA, followed by probe sonication. The CF outside the vesicles was then 
removed by dialysis against 50 mM Tris, 150 mM NaCl (to match the osmotic strength 
inside the vesicles) at 37oC, or by five to six consecutive Micro Bio-spin 30 columns 
(Bio-rad) equilibrated with the same buffer. The spin column was more effective for CF 
removal than dialysis.  
At 37oC, 4 mM Ca2+ was added to the aforementioned DPPC/PI SUVs, followed 
by the titration of SP-D. The fluorescence of CF was measured at 525 nm. As a control 
for complete leakage of CF, 1% (v/v) TX-100 was added to the vesicles. The addition of 
the detergent caused about a 3-fold increase in emission.  
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The final total lipid concentration was determined by 31P NMR, where the 
phosphodiester resonance of DPPC and PI (not completely resolved under the 
experimental condition) was integrated and compared to the integral of the external 
standard NaH2PO4. 
 
2.2.8 Vesicle morphology monitored by negative staining transmission electron 
microscopy (TEM) 
The TEM study was accomplished with the help and guidance of Mr. Donald 
Gantz at the Department of Physiology and Biophysics, Boston University School of 
Medicine, Boston, MA. The protocol was based on those previously reported (114). 
Briefly, DPPC SUVs or LUVs were preincubated with SP-A (or control buffer) and 
calcium under the identical conditions used in the NMR experiments (i.e., same 
concentrations of DPPC and SP-A incubation for the same time). These samples were 
then allowed to adhere to glow-discharged, carbon-coated copper grids for 30 min at 
room temperature, fixed with 2.5% glutaraldehyde for 5 min, and counterstained with 1% 
sodium phosphotungstate (pH 7.4). Micrographs were recorded on Kodak SO163 film in 
a CM12 transmission electron microscope (Philips). Images were developed in D19 and 
digitalized by a scanner. The sizes of the vesicles were measured using ImageJ (113). As 
illustrated in Fig. 2-3, the diameter of an individual vesicle (circled by dashed line) was 
measured from two perpendicular directions, and the average of these two measurements 
was used as the determined diameter value. All the non-overlapping vesicles in one to 
two films of each sample were measured (the solid circle in Fig. 2-3 gives an example of 
overlapping vesicles that were not measured). 
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Figure 2-3. TEM image of 0.2 mM DPPC LUVs in the absence of SP-A and Ca2+. The 
dash circle indicates an individual vesicle that is included in the measurement; the solid 
circle indicates overlapping vesicles that are not included in the measurement. 
 
 
2.2.9 Enzyme activity assay by 31P NMR 
The specific activity of PLC 1 toward PI was measured by monitoring myo-
inositol 1,2-(cyclic)-phosphate (cIP) and inositol-1-phosphate  (I-1-P) generation at fixed 
time points using 31P NMR spectroscopy (at 242.8 MHz on a Varian VNMRS 600 
spectrometer). NMR parameters were optimized based on those previously reported (115),  
including a 13.7 s pulse width (90o), recycle time of 3.1 s, 7310 Hz sweep width, digital 
resolution of 0.45 Hz/point, and probe temperature of 25oC. The substrate PI was 
embedded in LUVs mimicking physiological membranes (116), with a total lipid 
concentration of 10 mM or 0.5 mM. The amount of PLC 1 added (1–2 g) was adjusted 
so that less than 20% of PI was hydrolyzed within 30 min. The reaction was carried out in 
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50 mM HEPES buffer with 0.5 mM CaCl2, 100 mM NaCl, and 0.1 mg/ml BSA, pH 7.5, 
unless otherwise specified. When the total lipid concentration was 10 or 5 mM, 300 or 
400 l of enzyme/vesicles mixture was incubated at 37oC. At the desired time point, the 
reaction was quenched by adding 10% (v/v) acetic acid, 1 mM EDTA and a few drops of 
TX-100. The samples were then stored at −20oC before they were analyzed by NMR. 
Immediately before NMR measurement, samples were subjected to the following 
treatment: 1) more TX-100 was added when necessary to clarify the solution, ensuring 
solubilization of all vesicles; 2) the sample pH was adjusted to 6.1~6.5 by adding NaOH, 
so that the 31P resonance for bulk phosphodiester (PE, PC, SM, PS, and PI that was not 
hydrolyzed) was well resolved from the I-1-P resonance (whose chemical shift varies 
depending on pH); 3) 200 l D2O was added. An example of the NMR spectrum is 
shown in Fig. 2-4A. The cIP and I-1-P resonances were integrated and compared to the 
integral for the phosphodiester resonance in the absence of 1H decoupling. When the total 
lipid concentration was 0.5 mM, 5 ml of enzyme/LUVs mixture was incubated at 37oC. 
At the desired time point, the reaction was quenched by adding 5 drops of acetic acid and 
5 mM EDTA. An external standard of 0.1 mol G6P was also added. The lipids (PE, PC, 
SM, CH, and PI that was not hydrolyzed) were then removed with chloroform/methanol 
(2:1) extraction. The aqueous solution, containing products cIP and I-1-P, as well as 
external standard G6P, was frozen and lyophilized overnight. The dried solids were 
dissolved in 400 l D2O before NMR measurement. Examples of the NMR spectra in the 
absence (Fig. 2-4B) or presence of PIP2 (Fig. 2-4C) are shown. The cIP and I-1-P 
resonances were integrated and compared to the G6P resonance (differentiated from the 
I-1-P resonance with its two proximal singlets). In all our assays, both the intermediate 
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product cIP and the final product I-1-P were observed. The specific activity was 
calculated based on the sum of both products. 
 
Figure 2-4. 31P NMR spectra of PLC 1 hydrolysis products. (A) When the total lipid 
concentration was 10 mM and the phosphodiester resonance was used as internal 
standard; When the total lipid concentration was 0.5 mM and G6P was added as external 
standard in the absence (B) or presence (C) of PIP2. 
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Chapter 3 Lipid-specific Interactions of Pulmonary Collectins with 
Model Membranes 
3.1 Introduction 
Pulmonary collectins, surfactant proteins A (SP-A) and surfactant protein D 
(SP-D), are hydrophilic proteins synthesized and secreted by pulmonary alveolar type II 
cells. These two proteins play diverse and important roles in the innate immune response 
and lung surfactant homeostasis. Their interactions with most known ligands are 
calcium-dependent and involve their trimeric, C-type carbohydrate recognition domains 
(CRD).  
Preclinical data from rodents suggest the lung collectins can be potentially used in 
human therapy for diseases such as pneumonia, cystic fibrosis, and bronchopulmonary 
dysplasia (117–119). However, to produce recombinant oligomeric proteins with 
extensive post-translational modifications and complex assembly is technically 
challenging. Therefore, it is essential to define the minimum effective unit for each 
desired function of the collectins (45).  
Among their broad range of ligands, the best-defined endogenous phospholipid 
ligand for SP-A is dipalmitoylphosphatidylcholine (DPPC) (35), the major lipid 
component in lung surfactant. SP-D, on the other hand, preferentially binds to 
phosphatidylinositol (PI) (33). Previously, in vitro studies on the interactions of these two 
proteins with their lipid ligands often utilized lipids in the solid state (on thin-layer 
chromatography plates or coated on microtiter wells). In recent years, other methods such 
as infrared reflection-absorption spectroscopy (IRRAS) (10), atomic force microscopy 
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(AFM) (120,121) and NMR (122) have been applied to collectin-lipid interactions, where 
the lipid ligands are presented in model membranes in a physiologically relevant state.  
An insect expression system to obtain recombinant SP-A trimers (neck + CRD, or 
NCRD) (37,123), as well as a bacterial expression system for SP-D NCRD trimmers 
(124,125), have been developed in the laboratories of our collaborators Dr. Francis X. 
McCormack and Dr. Erika C. Crouch, respectively. We would like study how these 
truncated recombinant proteins interact with their phospholipid ligands, and how these 
interactions affect membrane properties, in order to understand the roles of these lung 
collectins in regulating surfactant structure and metabolism. 
In this work, we developed an NMR assay to monitor the interactions of SP-A or 
SP-D with their respective lipid ligands. This novel assay requires relatively simple 
operations to control the phase of the lipid aggregates and distinguish a specific lipid in 
lipid mixtures. 
 
3.2 Results 
3.2.1 The interactions of SP-D with model membranes 
In the initial experiments, the interactions of trimeric SP-D with model 
membranes were studied by 1H NMR. To imitate alveolar surface membranes, 
perdeuterated DPPC (1,2-dipalmitoyl-d62-sn-glycero-3-phosphocholine-1,1,2,2-d4-
N,N,N-trimethyl-d9, denoted as 
2H-DPPC) or proteo DPPC (1,2-dipalmitoyl-sn-glycero-
3-phosphocholine, denoted as 1H-DPPC), or a mixture of both were used as a matrix (the 
“host” lipid) for solubilizing a variety of other lipids (PI, DOPG, DOPMe) as the “guest” 
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lipid. The guest lipids were fixed at 20 mol%. This deuterated-host/proteo-guest 
membrane system made it possible to monitor a specific lipid in a lipid mixture since 
only the proteo lipids are “visible” by 1H NMR. Additionally, the phospholipid ligands 
are in solution phase, as opposed to being presented in solid phase in many of the 
previous approaches. Here, the linewidth of 1H resonances is monitored because of the 
reciprocal relationship between linewidth (1/2) and spin-spin relaxation time (T2). 
1/2 = 1/(T2) 
T2 reflects reversible exchange of nuclei in solution, and in this case the exchange of 
interest is that between phospholipids in the membrane bilayer with and without the SP-D 
bound. Fast exchange is assumed, given that SP-D has a moderate affinity for PI (the 
apparent Kd to PI for rat SP-D NCRD trimers is reported to be on the order of 10
−8 M 
(41)). If the assumption is valid, a single, broadened resonance would be observed upon 
the addition of the SP-D to the model membrane.  
3.2.1.1 SP-D broadens 1H resonance assigned to PI chain methylenes 
We first monitored half-height linewidth changes of 1H resonances upon adding 
rat SP-D NCRD by using 1 mM 2H-DPPC/0.25 mM 1H-PI SUVs system in the presence 
of 4 mM Ca2+. Unfortunately the headgroup region (3.5–5 ppm) was obscured by other 
components in the SUVs solution, in particular EDTA. However, we were able to 
observe a moderate and reproducible linewidth change for the 1H resonance assigned to 
the methylene chains (~1.4 ppm) of the PI (since all the DPPC methylene chains are 
deuterated and thus “invisible” in 1H NMR), whereas the resonance assigned to the 
terminal methyl group (~1.0 ppm) showed minimal or no change (Fig. 3-1). On the other 
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hand, an attempt to use 31P NMR to monitor linewidth change was not successful because 
the phosphate headgroups of DPPC and PI were not well resolved under the experimental 
condition (data not shown). Therefore, in the following SP-D studies, we mainly 
monitored the linewidth change of the methylene resonances using 1H NMR. 
 
Figure 3-1. Methylenes and end-methyl region (0.4–2.0 ppm) of 1 mM 
2H-DPPC/0.25 mM 1H-PI  SUVs 1H NMR spectra in the absence (A) or presence (B) of 
0.32 mg (34 M) trimeric rat SP-D NCRD. 
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3.2.1.2 SP-D binds specifically to PI 
Trimeric rat SP-D NCRD was titrated into SUVs containing anionic 
phospholipids PI, DOPG, DOPMe or DOPS, and the results are shown in Fig. 3-2. In 
these experiments, SUVs composed of 1 mM 2H-DPPC and 0.25 mM 1H-guest lipid were 
prepared in the presence of 4 mM Ca2+, followed by titrations of a total of 200 or 250 l 
SP-D (1–1.3 mg/ml) in five aliquots. The data were normalized by using the molar ratio 
of SP-D to the guest lipids. In Fig. 3-2, DOPG, DOPMe and DOPS essentially showed no 
change in linewidth as SP-D was added. In contrast, PI showed a 10–14 Hz change in 
linewidth, which is a considerable effect given the errors of the experiments and the size 
of the vesicles involved.  The results clearly demonstrated a specific, dose-dependent and 
saturable interaction of SP-D NCRD with PI, which is consistent with previous studies 
with full-length SP-D (either native protein isolated from bronchoalveolar lavage fluid or 
recombinant protein expressed in mammalian cells) (33,34,126). In addition, the initial 
linewidths of these SUVs showed noticeable differences, with PI larger than the other 
lipids. However, these PI-containing SUVs prepared on various occasions exhibited very 
similar initial linewidths (70–75 Hz, data not shown). The variation in initial linewidth 
for PI compared to other phospholipids doped into the host matrix may reflect the 
differences in fluidity and sizes of the vesicles due to their levels of saturation on the acyl 
chains: while synthetic DOPMe, DOPG and DOPS are unsaturated on both acyl chains, 
extracted PI from natural sources has a mixture of saturated and unsaturated acyl chains. 
It could also reflect clustering of the PI in the vesicles (127). 
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Figure 3-2. The methylene linewidths as trimeric rat SP-D was titrated into 1 mM 
2H-DPPC/0.25 mM 1H-guest lipid SUVs in the presence of 4 mM Ca2+. The guest lipid 
was PI (), DOPMe (), DOPG (), or DOPS (), respectively. The data were 
normalized by using molar ratio of SP-D to guest lipid. The PI curve was fit with Eqn.2-1, 
while the others were processed with linear fit, assuming there were very little changes. 
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3.2.1.3 Calcium enhances the specific binding of SP-D to PI 
The effects of Ca2+ on SP-D binding of PI were examined. In these experiments, 
SUVs composed of 1 mM 2H-DPPC and 0.25 mM 1H-PI were prepared in the presence of 
2, 4 or 8 mM Ca2+. A total of 250 l trimeric rat SP-D NCRD (1.3 or 1.4 mg/ml) was 
titrated in five aliquots into 500 l SUVs described above, and the results are shown in 
Fig. 3-3. R0.5, the SP-D/PI ratio needed for half the maximum change in linewidth 
(defined in Eqn. 2-1), decreased as the concentration of Ca2+ increased (Fig. 3-3B). In 
other words, Ca2+ reduced the amount of SP-D needed to broaden the PI resonance to the 
same level. This result shows that Ca2+ interaction can prime SP-D for binding to the 
vesicles containing PI. In addition, at fixed total phospholipid concentration, b, the 
extrapolated maximum change in linewidth (defined in Eqn. 2-1), showed little variation 
with varied Ca2+ levels (Fig. 3-3B), indicating a limiting linewidth change of 20 Hz 
caused by the SP-D.  
The Ca2+ dependence in the interaction between SP-D and PI had been 
demonstrated in a variety of studies (33,34,41,126), suggesting the involvement of the 
inositol moiety of PI as well as the Ca2+–coordinating residues in the CRD of the SP-D. 
Ca2+ neutralizes the acidic side chains of the SP-D, permitting close contact between the 
protein and the membrane surface. This may allow all three subunits of the CRD to 
interact simultaneously with the surface, orienting the neck domain away, and thus 
positioning the trimers for more extensive oligomerization (45).  
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Figure 3-3. Effects of Ca2+ on SP-D interaction with PI-containing SUVs. (A) 
Comparison of linewidth change induced by trimeric rat SP-D when 1 mM 
2H-DPPC/0.25 mM 1H-PI SUVs were in the presence of 2 mM (), 4 mM () or 
8 mM () Ca2+. All curves were fit with Eqn. 2-1. (B) Parameters generated from curve 
fitting.  
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3.2.1.4 SP-D has a stronger line-broadening effect on LUVs containing PI 
The effects of vesicle size on SP-D binding of PI were also examined. In these 
experiments, trimeric rat SP-D NCRD was titrated into SUVs or LUVs of the same 
composition, namely 1 mM 2H-DPPC and 0.25 mM 1H-PI, in the presence of 4 mM Ca2+. 
As shown in Fig. 3-4, the initial linewidth of the PI bulk methylene resonance was 
102.2 Hz and 70.5 Hz in LUVs and SUVs, respectively, reflecting the size difference of 
the vesicles. At SP-D/PI molar ratio of 0.09, there was a 170 Hz increase in linewidth 
with the LUVs, compared to an 8 Hz increase with the SUVs. Moreover, the extrapolated 
maximum linewidth change was 182 Hz and 25 Hz for the LUVs and the SUVs, 
respectively. Therefore, SP-D NCRD clearly had a much stronger line-broadening effect 
on LUVs than SUVs. This suggests that the SP-D prefers a flat surface, which, compared 
to a highly curved surface, might be more easily accessed by all three subunits of the 
SP-D NCRD trimers simultaneously. Interestingly, during the breathing process, the 
curvature of the surfactant films at the air–water interface varies as the alveoli expand or 
compress. This could in turn lead to a change in the association of the SP-D with the lipid 
films. However, whether the preference for flat surface of the SP-D carries any 
physiological significance remains unclear. 
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Figure 3-4. Comparison of linewidth change induced by trimeric rat SP-D between 
LUVs () and SUVs () of the same lipid composition (1mM 2H-DPPC/0.25 mM 
1H-PI), in the presence of 4 mM Ca2+. Both curves were fit with Eqn.2-1. 
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3.2.1.5 Species difference in SP-D affinity for PI 
Previously, the primary carbohydrate binding site of SP-D (called “SP-D groove”) 
has been identified (39). The comparison between the amino acid sequences of SP-D 
from rat and human reveal that some of the residues flanking the SP-D groove are not 
conserved. For example, at positions 324 and 325 of the mature human SP-D, there are 
two aspartates, which are substituted by two asparagines in the rat SP-D; Arg343 of 
human SP-D is substituted by lysine in rat SP-D. Results from our collaborators indicate 
that the difference in these residues plays a role in the different ligand preferences 
between the two species (41,125).  
To assess the interactions of PI with SP-D from different species, we used 1 mM 
2H-DPPC/0.25 mM 1H-PI SUVs system in the presence of 4 mM Ca2+. Trimeric rat SP-D 
NCRD (rSP-D), trimeric human SP-D NCRD (hSP-D WT), or trimeric human SP-D 
NCRD D324N/D325N/R343K triple mutant that resembles the rat SP-D (hSP-D NNK) 
was titrated into the SUVs solution, and the results are shown in Fig. 3-5. The 
extrapolated maximum change in linewidth (b) was 13.4 Hz, 8.4 Hz and 3.3 Hz for 
rSP-D, hSP-D NNK and hSP-D WT respectively, indicating more perturbation for PI by 
rSP-D than hSP-D WT, which is consistent with previous studies (41). Interestingly, the 
human SP-D NNK mutant showed an increased line-broadening effect when compared 
with the human WT, indicating an enhanced interaction with PI. However, this NNK 
mutant still had an almost two-fold lower perturbation of the methylene resonance than 
that shown by rat SP-D, suggesting that the differences of interaction with PI between 
SP-D from these two species are more than those three mutated residues, thus, other 
residues are likely to affect the interaction with the membrane as well. In addition, 
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through these experiments, we demonstrate that the novel NMR assay can be a powerful 
tool to obtain information on SP-D interactions with its ligands. 
 
Figure 3-5. Comparison of the perturbation of PI acyl chains among rat SP-D (), human 
SP-D wild type () and human SP-D NNK mutant (). The rat SP-D curve was fit with 
Eqn. 2-1; however, human SP-D (both wildtype and NNK mutant) did not fit well with 
Eqn.2-1, thus a hyperbolic model (where the cooperativity coefficient [m] in Eqn. 2-1 
was fixed at 1) was used instead. 
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3.2.1.6 Cooperative perturbation of lipid packing by SP-D 
The dynamics of SP-D binding to PI-containing SUVs were probed by varying 
the concentration and/or composition of the 2H-DPPC/1H-PI SUVs system. A first 
experiment was to prepare a 2H-DPPC/1H-PI SUVs system with doubled 1H-PI 
concentration (0.50 mM) but fixed molar ratio (20 mol%) in the 2H-DPPC matrix, 
followed by similar titrations of trimeric rat SP-D NCRD as described earlier. By 
comparing the two sets of data (Fig. 3-6), it is clear that more SP-D is required to get the 
same line-broadening when the amount of PI was increased. The consistency within these 
two sets of data confirms that the specific binding of SP-D really perturbs PI methylene 
chains in the vesicle, whereas the good fit with the cooperative model strengthens a 
hypothesis that SP-D binding to PI is cooperative (possibly clustering of PI molecules 
mediated by SP-D). 
To further examine the impact of SP-D on lipid packing when it binds to vesicles 
containing PI, we designed the following three DPPC/PI SUV systems: (A) 1 mM 
2H-DPPC and 0.25 mM 1H-PI; (B) 0.75 mM 2H-DPPC, 0.25 mM 1H-DPPC, and 
0.25 mM 1H-PI; (C) 1 mM 1H-DPPC and 0.25 mM 1H-PI. These SUVs were all sonicated 
in the presence of 4 mM Ca2+. The differences among these SUV systems lie in the 
proteo-lipid content: in System A, PI is the only proteo-lipid; in System B, proteo-lipids 
are half DPPC and half PI; in System C, all the DPPC and PI are proteo-lipids. The 
results of trimeric rat SP-D NCRD titrations are shown in Fig. 3-7. The linewidth change 
observed (~6 Hz when SP-D/PI is over 0.1) with the System C curve (where both PI and 
DPPC acyl chains were ‘visible’ in 1H NMR) suggests not only PI acyl chains, but also 
DPPC acyl chains, were disturbed upon SP-D binding; otherwise minimal linewidth 
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change would have been observed in this system because the undisturbed DPPC chains 
would obscure the linewidth change caused by perturbation of the PI chains. In addition, 
comparison of the System A curve (where only PI was “visible”) with the System B 
curve (where the “visible” 1H-DPPC and 1H-PI have a ratio of 1:1), shows that DPPC 
methylene chains were not perturbed to the same extent as PI, since there is discernible 
difference in the extents of line-broadening for the two curves. The results imply that PI 
on the vesicle surface provides a “handle” for SP-D to “grab” onto the surface. Upon 
“hopping” onto the bilayer surface, SP-D further perturbs the lipid packing, and hence 
broadens the linewidths of both PI and DPPC methylene chains. The implication that 
SP-D can perturb lipid packing could possibly link to events such as re-organization of 
surfactant ultrastructure and induced membrane leakage by SP-D (128).  
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Figure 3-6. Comparison of linewidth change induced by trimeric rat SP-D between 
2.0 mM 2H-DPPC/0.50 mM 1H-PI SUVs system () and 1.0 mM 2H-DPPC/0.25 mM 
1H-PI SUVs system (), both with 4 mM Ca2+. Both curves were fit with Eqn. 2-1. 
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Figure 3-7. Comparison of line-broadening effects of rat SP-D on PI and DPPC acyl 
chain methylene resonances. System A (1mM 2H-DPPC/0.25 mM 1H-PI) is shown as 
solid squares (), System B (0.75 mM 2H-DPPC/0.25 mM 1H-DPPC/0.25 mM 1H-PI) is 
shown as open diamonds (), and System C (1 mM 1H-DPPC/0.25 mM 1H-PI) is shown 
as solid circles (). All curves were fit with Eqn. 2-1. 
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3.2.1.7 Perturbation of lipid packing by SP-D has no significant impact on vesicle 
integrity 
To determine whether the perturbation of the phospholipid acyl chains causes 
DPPC/PI vesicle leakage, vesicle leakage assays using entrapped, self-quenched 
6-carboxyfluorescein were performed. As shown in Fig. 3-8, the leakage of CF slightly 
increased as SP-D was titrated into DPPC/PI (4:1) SUVs. When SP-D/PI molar ratio was 
above 0.05, the leakage percentage remained below 7%, whereas the 1H resonance 
assigned to PI methylenes was significantly broadened (the linewidth change was greater 
than 10 Hz). The comparison of linewidth change and leakage in the same range of 
SP-D/PI ratio implies that when the vesicle packing was perturbed by SP-D, the vesicle 
integrity was not significantly compromised, suggesting that when SP-D interacts with PI, 
the perturbation of lipid packing and induced vesicle leakage are two separate processes. 
However, the vesicles might still become permeable when a higher level of SP-D is 
present.  
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Figure 3-8. 1H linewidth change () and percentage of 6-carboxyfluorescein leakage () 
as a function of the molar ratio of SP-D to PI. In both the NMR assay and the leakage 
assay, DPPC/PI (4:1) SUVs with 4 mM Ca2+ were used. 
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3.2.2 The interactions of SP-A with model membranes 
Trimeric rat SP-A NCRD showed minimal binding to mannan and some 320 
glycans in array analysis (Dr. Erika C. Crouch, unpublished data). To determine whether 
this recombinant protein can bind to phosphatidylcholine (PC), we utilized a NMR assay 
similar to that used in the SP-D experiments. Here, we used three different PC molecules 
to prepare vesicles: DPPC, a saturated PC that is the best-defined endogenous 
phospholipid ligand for SP-A; POPC, an unsaturated PC with a much lower phase 
transition temperature (Tm for POPC is around −2
oC, whereas Tm for DPPC is around 
41oC for LUVs and lowered to about 38oC for SUVs); and DMPC, a saturated PC with 
shorter chain length and a phase transition temperature between DPPC and POPC (Tm for 
DMPC LUVs is 26oC and for SUVs the value is ~23oC). To keep the PC membranes in a 
liquid-crystalline phase, the experimental temperatures were set above their respective 
phase transition temperatures: 37oC for POPC and DMPC, 42oC for DPPC. 
3.2.2.1 SP-A causes line broadening of 1H resonances of PC 
In the presence of 4 mM Ca2+, the trimeric rat SP-A NCRD was titrated into 
SUVs containing 0.2 mM DPPC or POPC. Linewidths of 1H resonances assigned to the 
methylene chains (~1.4 ppm), the terminal methyl group (~1.0 ppm), and the choline 
head group (~3.4 ppm) of PC were monitored by NMR. The NMR spectra of DPPC 
SUVs, with 4 mM Ca2+, in the absence or presence of SP-A, are shown in Fig. 3-9. These 
two spectra clearly illustrate the substantial line broadening effect SP-A had on DPPC 
chain-methylenes and terminal methyl resonances. In fact, significant linewidth increases 
were observed with both DPPC and POPC SUVs upon the addition of SP-A (Fig. 3-10A 
and B). Compared to the line broadening effects of SP-D on PI-containing SUVs 
58 
 
(Fig. 3-1), the addition of SP-A not only broadened the 1H resonance assigned to the 
methylene chains of PC (by 60–80 Hz), but also broadened the 1H resonance assigned to 
the terminal methyl group of the PC chains (by 30–60 Hz). Additionally, unlike the SP-D 
experiments, where the inositol head group of the ligand PI was obscured by buffer 
contents in the same chemical shift region in 1H NMR, we were able to observe and 
monitor the distinct 1H resonance assigned to the three N-linked methyl groups of the PC 
choline head group (a singlet at ~3.4 ppm). The linewidth of this head group resonance 
was also increased (by around 20 Hz) when SP-A was added to the PC vesicles.  
Next, the line-broadening effect of SP-A on PC LUVs was examined. In the 
presence of 4 mM Ca2+, the trimeric rat SP-A NCRD was titrated into LUVs containing 
0.2 mM DPPC, POPC, or DMPC. As shown in Fig 3-10C, D and E, linewidths of 1H 
resonances assigned to the methylene chains, the terminal methyl group, and the choline 
head group of the three PC molecules were all increased, by 50–70 Hz, 30–80 Hz, 20–
30 Hz, respectively. In addition, while SP-D clearly showed a much greater 
line-broadening effect on LUV than on SUV (Fig. 3-4), SP-A did not appear to be as 
sensitive to the size of the vesicles, as evidenced by the similar linewidth increases with 
SUV and LUV. 
It is interesting to note that, in both SUVs and LUVs, DPPC resonances appeared 
to exhibit the largest initial linewidths in the absence of protein (Fig 3-10), reflecting the 
difference in overall fluidity of these PC membranes. POPC vesicles are likely to be more 
fluid than DPPC vesicles because of the unsaturated acyl chains, as well as the greater 
temperature difference between its Tm and the experimental temperature. In fact at 42
oC 
the LUVs are likely to have some coexistence of gel with the liquid crystalline phase. In 
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the same fashion, DMPC vesicles are likely to be more fluid than DPPC vesicles. 
Nevertheless, the difference in membrane fluidity did not seem to result in a difference in 
SP-D line broadening effect, suggesting that SP-A could interact with lipids in either 
liquid crystalline phase or gel phase. 
 
Figure 3-9. Methylenes and end-methyl region (0.4–2.0 ppm) of 0.2 mM DPPC SUVs 
1H NMR spectra in the absence (A) or presence (B) of 75 g trimeric rat SP-A.       
A 
B 
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Figure 3-10. Linewidth of PC 1H resonances as a function of the molar ratio of SP-A to 
PC. Trimeric rat SP-A NCRD was titrated into 0.2 mM (A) DPPC SUV, (B) POPC SUV, 
(C) DPPC LUV, (D) POPC LUV, and (E) DMPC LUV. The vesicles were all in D2O 
containing 10 mM imidazole, in which 4 mM Ca2+ was subsequently added. Measured 
linewidths include 1H resonances assigned to methylene chains (), acyl chain terminal 
methyl groups (), and methyl groups of the choline head group (). 
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3.2.2.2 NaCl abolishes the line-broadening effect of SP-A on the PC choline head 
group but not on the acyl chains 
The line broadening effect of SP-A on PC vesicles was examined in the presence 
of salt and compared to the results in its absence. Like the previous experiments, the 
trimeric rat SP-A NCRD was titrated into SUVs or LUVs containing 0.2 mM DPPC and 
4 mM Ca2+. The only difference was that 150 mM NaCl was added to the 10 mM 
imidazole D2O buffer that had been used previously. As shown in Fig. 3-11A, the 
presence of 150 mM NaCl completely eliminated the line broadening effect SP-A had on 
the choline head group of DPPC in SUV or LUV, indicating that the primary interaction 
of SP-A with the choline moiety is electrostatic. In contrast, the DPPC acyl chain 
resonance was still broadened regardless of the presence of NaCl (Fig. 3-11B), especially 
in the case of DPPC SUV, where the 1H resonance of chain methylenes was broadened to 
the same extent with or without NaCl. The methylenes in LUVs may seem to exhibit a 
smaller linewidth change when NaCl was present, but under this condition the initial line 
was very broad even before adding SP-A, making the measurement of linewidth much 
more difficult and prone to errors. Moreover, the line-broadening of the acyl chain 
terminal methyls induced by the SP-A (Fig. 3-11C), as well as the line shape change (see 
Section 3.2.2.3) observed with DPPC LUVs in 150 mM NaCl, suggest that SP-A still 
interacted with this region of the PC molecule. These results suggest that SP-A has two 
separate binding sites: one for the PC head group and a second region that interacts with 
the phospholipid acyl chains. In the presence of excess anions and cations, the binding of 
the hydrophobic chains remains the same (as measured by the linewidth changes as the 
protein is titrated into the solution), whereas the binding interaction with the choline has 
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been altered and likely weakened since the increased line broadening no longer occurs. 
This offers an explanation for the difficulty in obtaining crystallographic data for the 
location of the PC binding site. In fact, so far only a bound buffer molecule (MES), 
resembling the phosphocholine moiety in size, shape, and charge, has been observed in a 
crystal structure—the morpholino ring of the MES buffer stacking over the aromatic ring 
of Tyr164 (37). It would be interesting to see if the site-directed mutation at Tyr164 of 
SP-A causes any change in the line-broadening effect on the PC choline head group using 
the current NMR assay.  
 
Figure 3-11. 1H linewidth changes of (A) choline methyls, (B) acyl methylenes, and (C) 
acyl chain terminal methyls of DPPC induced by SP-A in the absence (solid symbols, 
 for SUVs,  for LUVs) or presence (open symbols,  for SUVs,  for LUVs) of 
150 mM NaCl.  
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3.2.2.3 The emergence of a new resonance 
As the trimeric rat SP-A NCRD was titrated into DPPC LUVs, in addition to the 
broadened resonances as previously described, a “new” resonance appeared at around 
1.8 ppm when a high level of SP-A (the concentration of added SP-A exceeded 6 M,  or 
molar ratio of SP-A to DPPC exceeded 0.03) was present. The emergence of this 
prominent resonance with DPPC SUVs requires a higher level of Ca2+ (a total of 8 mM) 
in addition to the higher level of SP-A (~10M). However, if 10 mol% cholesterol or 
1 mol% of an anionic phospholipid DOPMe was embedded in the DPPC SUV, only a 
high level of SP-A (greater than 6 M) was required (no increase in Ca2+ needed). The 
new resonance at 1.8 ppm can be observed with other PC membranes as well. For 
example, with DMPC LUVs and POPC SUVs, the new resonance can be seen when a 
higher level of Ca2+ (a total of 8 mM) as well as a higher level of SP-A (~10 M) was 
present. The appearance of a new resonance downfield of the methylene resonance (an 
example is shown in Fig. 3-12) might be explained by a slow exchange (compared to 
NMR timescale) between the PC molecules far from and in the vicinity of the bound 
SP-A on the membrane surface. It also may be the -CH2 of the chains and it appears 
larger because the motions of the bulk CH2 groups in the acyl chain are dramatically 
broadened and in slow exchange with a smaller amount of unaffected PC. Another 
explanation could be that SP-A causes fusion or another change in particle morphology 
that promotes this change. Regardless of the reason, SP-A has strong effects with the acyl 
chains of PC.  
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Figure 3-12. The 1H NMR spectrum of 0.2 mM DPPC/10 mol% cholesterol SUVs, in the 
presence of 4 mM Ca2+ and 5.8 M SP-A (SP-A/DPPC ratio equals 0.029).  
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3.2.2.4 SP-A binding did not cause vesicle fusion 
Since SP-A binding can cause substantial line broadening of PC resonances, and 
in some cases, a dominant resonance at the -CH2 chemical shift that has more intensity 
than (CH2)n or -CH3 in high resolution spectra, we next investigated if vesicle fusion 
also occurred. Here we used negative staining transmission electron microscopy (TEM) 
to visualize the vesicles and compile their size profiles in the absence or presence of 
SP-A. The experimental procedure was described in Section 2.2.10. The results of DPPC 
LUVs and SUVs are illustrated in Fig. 3-13 and Fig. 3-14, respectively. In the absence of 
SP-A, the diameters of DPPC LUVs were distributed in the range of 130 ± 60 nm. 
Interestingly, when SP-A was present (SP-A/DPPC molar ratio = 0.02), there appeared to 
be more vesicles having a diameter below 70 nm, resulting in a wider distribution and a 
slight shift of the center to 110 nm. The diameters of DPPC SUVs in the absence of SP-A 
ranged from 20 to 44 nm, centering around 27 nm. In the presence of SP-A (SP-A/DPPC 
molar ratio = 0.06), a very similar size distribution remained, without a drastic increase in 
the number of vesicles having a diameter above 50 nm. Overall, there did not seem to be 
a major change in vesicle size distribution with either DPPC SUVs or LUVs. Our results 
showed that the binding of the recombinant trimeric rat SP-A, at least in our experimental 
conditions, did not cause vesicle fusion. Therefore the observed line broadening was not 
a result of vesicle fusion. 
Studies have shown that, although not directly interacting with lipid membranes, 
the N-terminal segment of SP-A is required for lipid aggregation (129). The trimeric 
SP-A used in our experiments contained only the neck and CRD domains, lacking the 
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N-terminal segment of the full-length protein, which explains why vesicle fusion was not 
observed. 
 
Figure 3-13. TEM images of 0.2 mM DPPC LUVs in the (A) absence and (B) presence of 
SP-A (SP-A/DPPC=0.02) and 4 mM Ca2+. The corresponding size distributions compiled 
from (A) and (B) are illustrated in (C) and (D), respectively. (E) is an overlap of the 
histograms of vesicles sizes when DPPC was in the absence or presence of SP-A. 
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Figure 3-14. TEM images of 0.2 mM DPPC SUVs in the (A) absence and (B) presence of 
SP-A (SP-A/DPPC=0.06) and 4 mM Ca2+. The corresponding size distributions compiled 
from (A) and (B) are illustrated in (C) and (D), respectively. (E) is an overlap of (C) and 
(D).  
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3.3 Discussion 
Results of the NMR assays clearly demonstrated that the recombinant trimeric rat 
SP-D specifically binds to PI embedded in the vesicles (Fig. 3-2). This interaction alters 
at least part of the chain motion since the linewidth of the acyl methylene resonance of PI 
increased. Previously, crystallographic analysis of SP-D with PI head group analogs 
(myo-inositol and I-1-P) directly implicated the involvement of CRD residues and a 
coordinated calcium ion in PI binding (41). Our NMR data complement the 
understanding of SP-D/PI interaction by showing that SP-D binding also constrains the 
acyl chain movements of the PI molecules, either by direct association of SP-D with the 
acyl chains or conferred from the constraints placed on the inositol head group. It has 
been suggested that the interaction of SP-D with PI is important for lipid organization and 
surfactant homeostasis. SP-D was found to be responsible for PI-dependent formation of 
atypical hexagonal tubules (27). A more recent study suggested that the strong influence 
SP-D had on surfactant ultrastructure may lead to the altered uptake and catabolism of the 
phospholipid-rich aggregates by alveolar type II cells, thereby regulating surfactant 
homeostasis (16). Besides, the interactions of SP-D with PI could also play a role in the 
innate immune response and host defense. For example, PI could be liberated at sites of 
active cellular injury. The recognition of certain pathogens that contain PI moieties, such 
as mycobacteria (130), could involve similar SP-D/pathogen interactions. 
Compared to the effect of the SP-D on PI-containing membranes, the SP-A has a 
much more pronounced effect on PC membrane dynamics, evidenced by the substantial 
linewidth increase of PC chain methylenes and terminal methyl resonances (Fig. 3-10). 
While the electrostatic interaction between the PC headgroup and the SP-A can be 
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screened with high salt, the changes in the PC acyl chains persist (Fig. 3-11). This 
indicates that the SP-A disturbs chain packing in a manner that reduces chain motions 
and thus broadens the acyl chain linewidths. Furthermore, the emergence of a new 
resonance downfield of the acyl methylenes in some circumstances (Fig. 3-12) suggests 
that there is a slow exchange between PC interacting with the SP-A and free PC in the 
membranes.  
Structurally, trimeric SP-A has a flatter, more hydrophobic surface than the 
trimeric SP-D, which explains why SP-A might be better suited to bind less-polar 
substrates. The affinity SP-A has for the hydrophobic moiety of PC molecules may also 
be responsible for the recognition of the lipid A component of LPS, which is important 
for the role SP-A plays in host defense. 
Previous studies have shown that SP-A is required in the formation of tubular 
myelin and other large surfactant aggregates. To stabilize curved regions of the lamellar 
bodies, it is very likely that SP-A controls, and even constrains, chain motions. This 
would be consistent with the observation that the populations of PC LUVs had a larger 
proportion of smaller vesicles in the presence of the SP-A. 
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Chapter 4 Interaction of the Isolated EF-hand Domain of Mammalian 
PLC  with Model Membranes 
4.1 Introduction 
Mammalian phosphoinositide-specific phospholipase C (PLC) enzymes play an 
important role in cellular signaling by catalyzing the hydrolysis of phosphatidylinositol-
4,5-bisphosphate (PIP2). The hydrolysis generates two second messengers, inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium from 
the endoplasmic reticulum (55) and DAG activates protein kinase C (PKC) (56,57). 
These signal transduction cascades are essential for many cellular events, such as cell 
growth, proliferation, fertilization and secretion. Approximately 13 distinct isoforms of 
PLC have been described in mammals, and they are grouped into six subfamilies based 
on sequence homology: PLC(1–4), PLC(1,2), PLC(1,3,4), PLC(1), PLC(1) and 
PLC(1,2). These subfamilies differ in structure and mode of regulation. All members of 
the PLC family exhibit a multidomain structure that comprises the catalytic X and Y 
domains, the protein kinase C conserved region 2 (C2) domain, EF-hand domain, and 
pleckstrin homology (PH) domain (except for the sperm-specific PLC, which does not 
have a PH domain). In addition to the core conserved regions, some isoforms also contain 
subfamily-specific domains that contribute to their specific regulatory mechanisms. For 
example, the Src homology (SH) domains in PLC are important for its regulation by 
tyrosine kinase coupled receptors (89,131).  
Phospholipase C 1 (PLC 1), widely expressed in various cell types (90), is one 
of the smallest PLC isoforms that contain all the core conserved domains. The crystal 
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structures of the isolated PH domain and the PH domain deletion variant of PLC 1 have 
been solved separately (85,132). The PH domain of PLC 1 specifically binds to PIP2 and 
its head group IP3 (80), and the affinity for the former allows the PH domain to tether the 
PLC enzyme to the plasma membrane, where the catalysis is carried out in a processive 
manner (85). The C2 domain of PLC 1 has been shown to form a ternary complex with 
calcium and phosphatidylserine (PS), which activates the enzyme (133). The EF-hand 
domain of PLC 1 consists of four consecutive EF-hand motifs, pairwise distributed in 
two lobes, exhibiting a characteristic helix-loop-helix topology (85). While the structure 
of the EF-hand domain is known, very little is known about how that structure dictates 
function. The EF-hand motifs, found in all PLC isoforms, are necessary to express full 
PLC activity, as evidenced by the abolition of PLC activity resulting from the deletion of 
EF-hand residues (134,135). Based on the structural similarities between the PLC 1 
EF-hand and other calcium binding EF-hand proteins such as calmodulin, it has been 
suggested that the EF-hand domain of PLC 1 might serve a regulatory role through 
calcium binding. Elsewhere, interactions of the EF-hand domain with free fatty acids 
have also been suggested (103,136). Additionally, numerous EF-hand motifs containing 
proteins have been reported to be involved in lipid binding. For example, diacylglycerol 
kinase-, a multidomain enzyme, contains the EF-hand motifs and is regulated by lipids 
and calcium (137,138). 
In this work we used several biophysical methods and site-directed mutagenesis 
to characterize the interactions of the isolated EF-hand domain of PLC 1 with model 
membranes.  
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4.2 Results 
4.2.1 Secondary structure of the isolated EF-hand domain of PLC 1 and its 
mutants 
In the crystal structure of a truncated PLC 1 (85), three of the four EF-hand 
motifs are resolved and they interact closely with the C2 domain. When the EF-hand 
domain (and later its mutants) was expressed independent of the rest of PLC 1, CD 
spectroscopy was used to characterize the secondary structure (Fig. 4-1). The double 
minima at 208 and 222 nm indicated that the protein was well-folded and predominantly 
-helical. All the site-directed mutants exhibited similar spectra and only one of the triple 
mutants (R182A/K183A/K186A, see Section 4.2.4) is shown here. Measurement of the 
temperature dependence of the EF-hand domain folding (Fig. 4-2) showed a change in 
the CD signal consistent with a two-step unfolding transition. There is a broad initial loss 
of secondary structure with temperature that destabilizes about half the secondary 
structure—however, a more thermostable core remains—this may start to melt at the 
highest temperatures. A similar melting curve was obtained in the presence of 0.2 mM 
Ca2+ (Fig. 4-2). Therefore it appears that this isolated EF-hand fragment has a tight 
structural core but some of the helices unravel with increasing temperature. 
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Figure 4-1. Far-UV CD spectra of wild type (×) and triple mutant 
R182A/K183A/R186A (+) of PLC 1 EF-hand domain. The proteins were in PBS buffer, 
pH 7.4.  
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Figure 4-2. Temperature dependence of the PLC 1 EF-hand domain folding: wild type 
EF-hand protein in the absence () or presence () of 0.2 mM of Ca2+. Wavelength was 
fixed at 222 nm. The proteins were in PBS buffer. 
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4.2.2 Interactions between the isolated EF-hand domain of PLC 1 and fatty acid 
Previous work in our laboratory suggested that arachidonic acid (AA) binds to the 
isolated EF-hand domain, inducing conformational change that may play a role in 
calcium binding (103). Initially, I repeated the far-UV CD and the intrinsic tryptophan 
fluorescence emission experiments described in the report (103), substituting the 
previously used detergent dodecylmaltoside (DDM) with diC7PC as the micelle matrix. 
Comparable to the earlier report, adding AA/diC7PC mixed micelles (we used 1.5 mM 
diC7PC, which was above its Critical Micelle Concentration [CMC] of 1.4 mM) to EF 
caused a loss of negative ellipticity below 210 nm (Fig. 4-3).  
On the other hand, the changes in the intrinsic tryptophan fluorescence emission 
experiment were different from the previous report. As seen in Fig. 4-4, the addition of 
1.5 mM diC7PC to EF caused a 9% increase in intensity, followed by a 23% decrease in 
intensity when 100 M of AA was added next. This suggests that diC7PC and AA affect 
the local environment of the tryptophan (Trp144), and therefore interact with the protein, 
differently. It contrasts with the previous result (103), where the addition of 200 M 
DDM (above its CMC) to EF caused a roughly twofold increase in intensity, and further 
addition of 100 M AA produced no additional increase in EF fluorescence. Nevertheless, 
the change in fluorescence with the addition of AA, taken together with the far-UV CD 
result (Fig. 4-3), suggested that there was interaction between AA and the EF-hand 
domain.  
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Figure 4-3. Far-UV CD spectra of PLC 1 EF. All the solutions were in 10 mM sodium 
phosphate buffer, pH 7.5. All the spectra have been corrected by subtracting the buffer 
blank. (A) 0.04 mg/ml PLC 1 EF in the absence (thick solid line) or presence (dashed 
line: prior to the subtraction of the AA/diC7PC contribution; solid line: after the 
AA/diC7PC contribution has been subtracted) of 82 M AA/1.5 mM diC7PC; for 
comparison, AA/diC7PC alone is also shown (thick dotted line). (B) Difference spectra 
for the corrected PLC 1 EF + AA/diC7PC spectrum minus PLC 1 EF alone. 
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Figure 4-4. Intrinsic tryptophan emission spectra of PLC 1 EF. The EF concentration 
was 4.1 M (solid line). DiC7PC was added to 1.5 mM (short/long dashed line), followed 
by AA added to 100 M (dotted line). All the spectra have been corrected by subtracting 
the buffer. All the intensities are expressed relative to the tryptophan emission in the 
EF-only solution at 345 nm. 
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Following the setup of the intrinsic tryptophan fluorescence emission experiment, 
I further examined the effect of AA presented in vesicles (instead of micelles) on the 
isolated EF-hand domain. Initially, the titration of POPC SUVs containing 10 mol% AA 
into EF-domain protein solution caused a dose-dependent decrease in the tryptophan 
fluorescence (Fig. 4-5,). There was a 55% decrease in fluorescence emission (at 
345 nm) when a total lipid concentration of 6 mM was added. This appeared to be 
consistent with the fluorescence decrease caused by the addition of diC7PC/AA mixed 
micelles. However, when a fresh stock of AA was used to prepare the SUVs, the 
significant change in fluorescence was no longer observed with the addition of 
AA-containing SUVs (Fig. 4-5,). When 6 mM of lipid was added, there was only an 11% 
decrease in fluorescence; even when the total added lipid reached 9.6 mM, the decrease 
in fluorescence was still only 25%. In fact, the change in fluorescence induced by 
POPC/AA SUVs was comparable to that induced by POPC-only SUVs (Fig. 4-5,). 
Additionally, a repeat experiment using diC7PC/fresh-AA mixed micelles (that were 
added to EF) showed less than 5% change in fluorescence intensity (data not shown), 
which is also different from what we observed with the sample containing AA from an 
older stock (Fig. 4-4). These rather different results obtained from samples prepared from 
two different stocks of AA strongly suggested that the two stocks may not contain the 
same substance.  
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Figure 4-5. Comparison of the effects of AA-containing vesicles on the intrinsic 
tryptophan fluorescence of PLC 1 EF (20 M): EF-hand domain was mixed with SUVs 
consisted of 90 mol% POPC and 10 mol% AA that was from an old stock () or a fresh 
stock (); as a control, EF-hand domain was mixed with SUVs consisted of POPC only 
(). All the spectra have been corrected by subtracting the buffer or buffer plus 
respective vesicles, and normalized to the fluorescence intensity of the EF-only solution. 
The error bars indicate the standard deviation of at least two repeats. 
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Comparing the 1H NMR spectrum of each of these two AA stocks revealed that 
they indeed were vastly different (Fig. 4-6). The chemical shifts and the integration in the 
fresh AA stock spectrum (Fig. 4-6B, Fig. 4-6C) match very well with the chemical 
structure of AA (Fig. 4-6D); in contrast, there was clearly a loss of the olefinic proton 
signal (~5.4 ppm) in the old AA stock (Fig. 4-6A), indicating a loss of carbon double 
bonds in the AA molecules that may very well be caused by oxidation over time. 
Oxidized AA is likely to be more negatively charged than the original molecule, and 
therefore may have a higher affinity for the EF-hand domain due to electrostatic 
interactions. This could explain why an older stock of AA appeared to bind more tightly 
to the EF-hand domain than a fresh AA stock. The intrinsic tryptophan fluorescence data 
obtained with fresh AA samples indicate that the interaction between the EF-hand 
domain of PLC 1 and arachidonic acid was minimal. However, this raised the possibility 
that the EF-hand domain might bind anionic phospholipids specifically. 
 
Figure 4-6. 1H NMR analysis of arachidonic acid stocks in CDCl3. (A) NMR spectrum of 
the old stock of arachidonic acid; (B) NMR spectrum of the fresh stock of arachidonic 
acid; (C) proton assignment and integration based on (B); (D) chemical structure of 
arachidonic acid; letters a–g in blue indicate the proton assignment listed in (C). 
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proton assignment chemical shift (ppm) integration actual number of protons 
a 5.4 8.00 8 
b 2.8 6.24 6 
c 2.4 2.12 2 
d 2.1 4.33 4 
e 1.7 2.42 2 
f 1.3 6.37 6 
g 0.9 3.00 3 
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4.2.3 Interactions between the isolated EF-hand domain of PLC 1 and anionic 
phospholipids  
To further explore the binding partners for the isolated EF-hand domain of PLC 
1, I used several methods, including intrinsic tryptophan fluorescence, fluorescence 
resonance energy transfer, centrifugation-filtration, and NMR spectroscopy, to study the 
EF-hand domain binding to a variety of anionic phospholipids. When designing the lipid 
composition for presentation of the anionic ligands, we chose to use a moderate amount 
of zwitterionic phospholipid, POPC, to dilute the anionic phospholipids. 
Phosphatidylinositides, the substrates of PLC 1, are located in the inner leaflet of the 
plasma membrane, where anionic phospholipids represent only a moderate fraction of the 
membrane lipids. The inner leaflet is rich in PE and this is usually the major zwitterionic 
lipid, but PE vesicles are often metastable (this depends on chain length, degree of 
unsaturation, temperature and pH).  
 
4.2.3.1 Binding assay by intrinsic tryptophan fluorescence 
SUVs containing 80 mol% POPC and 20 mol% anionic phospholipid (PA, PS, 
and PG) or POPC-only SUVs were titrated into EF protein solutions. All SUVs 
containing anionic phospholipids increased the tryptophan fluorescence emission 
(Fig. 4-7A), whereas addition of POPC SUVs decreased the emission (Fig. 4-7B). The 
changes in tryptophan fluorescence (at 345 nm) as a function of total phospholipid 
concentration are shown in Fig. 4-8. The change induced by PA-containing vesicles 
(Fig. 4-8,) was biphasic: an increase up to 15% at concentrations below ~6 mM total 
lipids and a decrease at higher concentrations. The changes induced by PG- (Fig. 4-8,) 
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or PS-containing vesicles (Fig. 4-8,) did not vary much as the lipid concentration 
increased, and were less than 4% even as the lipid concentration reached 6 mM. The 
change induced by POPC vesicles (Fig. 4-8,) appeared almost linear, and the overall 
change was small—6% as the lipid concentration reached 6 mM. These results suggest 
that EF selectively interact with PA, which could be attributed to the charge and/or the 
smaller size of its head group. The decrease at higher PA concentrations may be caused 
by light scattering or vesicle aggregation. Interestingly, the addition of PC-only SUVs 
caused a decrease in tryptophan fluorescence emission, contrasting to the increases 
caused by mixing in SUVs containing anionic phospholipids. It might simply reflect the 
different fashions in which PC and the anionic phospholipids affect the local environment 
of Trp144. However, the almost linear fluorescence change induced by PC SUVs also 
raises the possibility that the major cause of the change is not binding but light scattering. 
Evidently, these data could be qualitatively informative, but hardly conclusive. It is 
difficult to extrapolate apparent dissociation constants from these data. This tryptophan 
fluorescence method, while useful for tight binding ligands, is problematic for 
phospholipids with lower affinity or whose binding has a smaller effect on protein 
fluorescence.  
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Figure 4-7. Intrinsic tryptophan emission spectra of PLC 1 EF with phospholipid 
vesicles. To 20 M EF-hand solution, (A) 0–9.6 mM POPC/POPA (80:20) SUVs, or (B) 
0–6 mM POPC SUVs, were added. Increasingly lighter color of the curves represents 
increasing vesicle concentrations. All the spectra have been corrected by subtracting the 
buffer or buffer plus respective vesicles of the same concentration. 
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Figure 4-8. Change in the tryptophan fluorescence intensity of PLC 1 EF-hand domain 
(20 M) at 345 nm as a function of total phospholipid concentration. The SUVs added to 
EF include: POPC/POPA (80:20) (), POPC/DOPG (80:20) (), 
POPC/DOPS (80:20) (), and POPC only ().I, the difference in fluorescence 
intensity in the absence and presence of vesicles; I0, the fluorescence intensity of EF-hand 
domain in the absence of any vesicles. All the spectra have been corrected by subtracting 
the buffer or buffer plus respective vesicles.  
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4.2.3.2 Binding assay by fluorescence resonance energy transfer 
An alternative binding assay utilizes fluorescence resonance energy transfer 
(FRET) where the tryptophan in the EF-hand domain serves as a donor and the 
dansyl-labeled phospholipid embedded in the membrane serves as an acceptor. SUVs of 
various compositions (all containing 1 mol% dansyl-PE) were titrated into EF protein 
solutions. All the dansyl-containing vesicles induced a dose-dependent decrease of the 
tryptophan fluorescence of the EF protein (Fig. 4-9). The changes in tryptophan 
fluorescence (at 345 nm) as a function of total phospholipid concentration are shown in 
Fig. 4-10. Within the vesicle concentrations we measured, we observed pronounced 
energy transfer (20%–56%) for each of the vesicle compositions, including POPC SUVs 
that did not contain any anionic phospholipids. The observed energy transfer indicates 
that the tryptophan and dansyl fluorophores are in close vicinity (within Ro, ~20 Å), 
which in turn suggests that binding indeed occurs between the EF-hand domain and the 
POPC. However, from the centrifugation-filtration vesicle binding assays, which will be 
described in the next section (Section 4.2.3.3), we conclude that EF does not bind to 
zwitterionic POPC vesicles in the absence of anionic phospholipids (Fig. 4-11A); NMR 
result also points to the same conclusion (Section 4.2.3.4, Fig. 4-16). Additionally, the 
increase in the tryptophan intrinsic fluorescence emission did not reach a plateau (which 
would indicate that the binding reaches saturation) with any of the vesicle compositions 
we tried, even when the total phospholipid concentration was in the millimolar range, 
suggesting a very weak binding of the EF-hand domain with any of these vesicles. 
Clearly, these data are very difficult to interpret. The complications are likely caused by 
light scattering of the vesicles, which becomes a prominent source of error when the 
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vesicle concentration is high. It should be pointed out that we tried minimizing the light 
scattering factor by subtracting the scattering background (the emission of protein in the 
presence of unlabeled vesicles), but unfortunately the complication remains. Similar to 
changes in intrinsic fluorescence, the FRET method appears to be problematic when the 
protein does not bind tightly to the target vesicles. 
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Figure 4-9. Tryptophan emission spectra of PLC 1 EF with dansyl-containing vesicles. 
To 20 M EF solution, (A) 0–12.0 mM POPC/POPA/dansyl-PE (80:20:1) SUVs , or (B) 
0–4.0 mM POPC/dansyl-PE (100:1) SUVs, were added. Increasingly lighter color of the 
curves represents increasing vesicle concentrations. 
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Figure 4-10. Energy transfer efficiency (E) as a function of total phospholipid 
concentration. The SUVs added to EF include: POPC/POPA/dansyl-PE (80:20:1) (), 
POPC/DOPG/dansyl-PE (80:20:1) (), POPC/DOPMe/dansyl-PE (80:20:1) (), and 
POPC/dansyl-PE (100:1) (). Unlabeled vesicles are used to subtract the scattering 
background for each of the titration series. 
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4.2.3.3 Binding assay by centrifugation-filtration 
In an effort to better estimate the apparent dissociation constants, the binding of 
the EF-hand domain of PLC 1 with various anionic phospholipid species was measured 
using a centrifugation-filtration vesicle binding assay (see Section 2.2.6.5 for 
experimental details). SUVs were used because the EF-hand domain showed much higher 
partitioning onto small versus large vesicles (Fig. 4-13 shows an example for the different 
partitioning of EF onto small and large vesicles of the same lipid composition). As 
visualized by SDS-PAGE, when the concentration of PC/PA SUVs mixed with EF 
increased, the amount of the free EF decreased (Fig. 4-11B), indicating an increase in the 
amount of EF partitioned onto the vesicles. The same trend was observed when SUVs 
containing other anionic phospholipid (PS or PG) were mixed with EF (SDS-PAGE not 
shown). The variation in the amount of EF partitioned onto SUVs was fit with a 
hyperbolic curve (Eqn. 2-3) to generate an apparent dissociation constant, KD (two 
examples are given in Fig. 4-12). This is not a true dissociation constant but an apparent 
KD that provides a way of comparing affinities of the EF-hand domain for various model 
membrane surfaces. As listed in Table 4-1, EF bound to SUVs containing 50 mol% 
anionic phospholipid (PA, PS, and PG) with moderate KD’s (on the order of 0.1 mM). In 
contrast, EF showed no partitioning onto zwitterionic POPC vesicles in the absence of 
anionic phospholipids, even when the PC concentration was increased to 6 mM 
(Fig. 4-11A). EF had slightly higher affinities for SUVs containing PA or PS than for 
those containing PG (Table 4-1). In the presence of 0.15 M NaCl, the KD’s were 
decreased compared to those in the absence of NaCl, although the maximum fractions of 
EF bound to SUVs (fmax) were lower (Table 4-1). Adding a considerable amount (0.15 M) 
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of salt did not abolish the binding, indicating that the binding of EF to SUVs containing 
anionic phospholipids is not solely electrostatic (which we explore in Section 4.2.5).  
It should be noted that the binding occurred in the absence of calcium (with 
0.1 mM EGTA present), and the presence of 0.5 mM Ca2+ did not dramatically affect 
binding for SUVs with anionic phospholipids (Table 4-2). There was a larger loss of 
binding to PC/PA SUVs with Ca2+ present compared to PC/PS. Interestingly, in all the 
known crystal structures of PLC 1, no calcium ion is found associated with the EF-hand 
domain, even though the enzyme is soaked in calcium or its analogs (85,139–141). The 
lack of requirement for calcium, taken together with the selective affinity for anionic 
phospholipids, suggest that basic residues of the EF-hand domain, rather than its acidic 
residues in coordination with calcium, are likely to contribute to the binding of the 
EF-hand domain to the membrane surfaces. We explore further on this topic in 
Section 4.2.4. 
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Figure 4-11. SDS-PAGE of free EF as a function of added vesicles: (A) POPC SUVs; 
(B) POPC/POPA (80:20) SUVs. Bulk phospholipid concentrations are indicated beneath 
each lane.  
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Figure 4-12. The fraction of EF bound (Eb/ET) as a function of total lipid concentration. A 
fixed amount of EF was mixed with PC/PS () or PC/PA () (1:1) SUVs. The lines are 
the least square fit to Eqn. 2-3, with an apparent KD 0.14±0.04 mM for PC/PS and 
0.12±0.02 mM for PC/PA. The error bars indicate the standard deviation of at least four 
repeats. 
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Figure 4-13. The fraction of EF bound (Eb/ET) as a function of total lipid concentration. A 
fixed amount of EF was mixed with small () or large () unilamellar vesicles of the 
same lipid composition. The lines are the least square fit to Eqn. 2-3. The error bars 
indicate the standard deviation of at least two repeats. 
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Table 4-1. Apparent dissociation constants and maximum fractions bound for EF-hand 
domain binding to anionic phospholipid-containing SUVs in the absence or presence of 
0.15 M NaCl. 
a This is the total concentration of phospholipids present for half of maximum binding. Errors 
were determined from the hyperbolic fit to the data. 
b This is the maximum fractions of EF bound to the vesicles. Errors were determined from the 
hyperbolic fit to the data. 
c The buffer was 20 mM Tris, 0.1 mM EGTA, pH 7.5. 
d The buffer was 20 mM Tris, 0.1 mM EGTA, 0.15 M NaCl, pH 7.5. 
 
Table 4-2. Apparent dissociation constants for EF-hand domain binding to anionic 
phospholipid-containing SUVs in the absence or presence of 0.5 mM Ca2+. 
SUV composition 
Apparent KD (mM) 
a 
Ca2+ = 0 mM b Ca2+ = 0.5 mM c 
POPC/DOPA (1:1) 0.12 ± 0.02 0.63 ± 0.17 
POPC/DOPS (1:1) 0.14 ± 0.04 0.14 ± 0.05 
a This is the total concentration of phospholipids present for half of maximum binding. Errors 
were determined from the hyperbolic fit to the data. 
b The buffer was 20 mM Tris, 0.1 mM EGTA, pH 7.5. 
c The buffer was 20 mM Tris, 0.5 mM CaCl2, pH 7.5. 
  
SUV composition 
Apparent KD (mM) 
a fmax 
b 
NaCl = 0 M c NaCl = 0.15 M d NaCl = 0 M c NaCl = 0.15 M d 
POPC/DOPA (1:1) 0.12 ± 0.02 0.087 ± 0.028 0.85 ±0.04 0.68 ± 0.06 
POPC/DOPS (1:1) 0.14 ± 0.04 0.085 ± 0.046 0.90 ± 0.08 0.52 ± 0.07 
POPC/DOPG (1:1) 0.25 ± 0.04 0.109 ± 0.097 0.97 ± 0.05 0.44 ± 0.11 
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4.2.3.4 Binding assay by 1H NMR 
While the centrifugation-filtration vesicle binding assay proves to be an effective 
method to compare affinities of the EF-hand domain for various model membrane 
surfaces, it does not offer dynamics information or differentiate the interaction of the 
protein with a specific type of phospholipid in mixed-component membranes. To this end, 
we applied the 1H NMR assay developed in the pulmonary collectins study (Chapter 3) to 
EF binding. We used commercially available, chain-deuterated DMPC (1,2-dimyristoyl-
d54-sn-glycero-3-phosphocholine, denoted as d54-DMPC) or proteo DMPC (1,2-
dimyristoyl-sn-glycero-3-phosphocholine) to mix with PA (fixed at 50 mol%). Since only 
the proteo lipid acyl chains are “visible” by 1H NMR, we could monitor PA acyl chains 
specifically and compare with proteo PC/PA. The experimental temperature was set at 
37oC to maintain the liquid crystalline phase of the vesicles. As shown in Fig. 4-14, when 
~45 M of EF-hand domain was titrated into 4 mM d54-DMPC/POPA (1:1) SUV or 
4 mM DMPC/POPA (1:1) SUV, the changes in 1H resonance linewidth were small — for 
both deuterated- and proteo-vesicle systems, the methylenes and the terminal methyl 
groups of the acyl chains, there was no more than a 4 Hz increase in linewidths. 
Therefore, unlike SP-A and SP-D, the unlabeled EF-hand domain did not have 
discernible line-broadening effect on model membranes at these experimental conditions. 
This suggests its primary interaction is with the phospholipid head groups. 
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Figure 4-14. Linewidth of phospholipid 1H resonances as a function of the amount of 
EF-hand domain of PLC 1 added. EF protein was titrated into 4 mM d54-DMPC/POPA 
(1:1) SUV (solid symbols ,) or 4 mM DMPC/POPA (1:1) SUV (open symbols ,). 
Measured linewidths include 1H resonances assigned to methylene chains (,) and acyl 
chain terminal methyl groups (,). 
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One way to enhance the protein-induced relaxation effect (that is, the 
line-broadening, or spin-spin relaxation rate (R2), observed in 
1H NMR spectra) is to add 
an electron spin label to the protein near a suspected binding site (142). The much larger 
magnetic dipole of the electron can relax nuclei up to 20 Ǻ away. The spin label we used, 
(1-oxyl-2,2,5,5-tetramethyl-3-pyrroline-3-methyl) methanethiosulfonate (MTSL), will 
specifically form a disulfide with any thiols, here the Cys residues. There are two Cys 
residues in the EF-hand domain of PLC 1, Cys148 and Cys188 (see Fig. 4-17 for the 
amino acid sequence). In order to achieve site-specific spin labeling, we generated two 
mutants, C148S and C188S, each with one Cys residue substituted by serine. After the 
labeling reaction, mutants C148S and C188S were reacted with MTSL at Cys188 and 
Cys148, respectively. The secondary structure of the labeled EF mutants was 
characterized using CD spectroscopy, and they exhibited similar spectra to the wild type 
protein (see Section 4.2.1), indicating that the mutation and labeling did not alter EF 
protein folding. As shown in Fig. 4-15, the line-broadening effect induced by EF binding 
was clearly enhanced by adding the spin label to the protein. Compared to the minimal 
linewidth increase (no more than 4 Hz) induced by the unlabeled EF, dose-dependent 
increases in linewidth were observed when similar amounts of labeled protein were added: 
the methylene chain resonances were broadened by 13–20 Hz, and the acyl chain 
terminal methyl resonances were broadened by 8–18 Hz. Interestingly, the spin label 
located at Cys148 (C148-SL) appeared to have a greater line-broadening effect on the 
1H resonances than the spin label at Cys188 (C188-SL). For example, the 1H resonance 
assigned to the acyl methylenes of PA (in 4 mM d54-DMPC/POPA (1:1) SUV) saw a 
linewidth increase of 20 Hz when 44 M C148-SL was added, while an increase of 13 Hz 
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was observed with the same amount of C188-SL (Fig. 4-15A). We expect the errors in 
measuring the linewidths to be less than the changes in titrations with unlabeled protein 
(less than 4 Hz), so the difference in the effect of the two spin-labeled proteins is real. 
The same trend was observed with other 1H resonances as well. This suggests that the 
membrane-binding site(s) on the EF-hand domain might be closer to Cys148 than Cys188. 
Further investigation using field-cycling NMR, an approach that can provide more 
information on membrane-docked proteins, such as the distance between the spin label on 
the protein and the phospholipid molecules, is in process. 
The line-broadening effects of the spin labeled EF had on membranes of various 
compositions were also compared. As shown in Fig. 4-16, SUV containing only PC 
showed no increase in linewidth with the addition of C188-SL. This is consistent with the 
centrifugation-filtration binding assay result (Fig. 4-11), that the EF did not bind to 
zwitterionic PC vesicles in the absence of anionic phospholipids. On the other hand, the 
linewidth increases observed with proteo DMPC/POPA SUV (22 Hz for acyl methylenes 
and 13 Hz for acyl chain terminal methyls when 49 M C188-SL was added) were 
greater than d54-DMPC/POPA (13 Hz for acyl methylenes and 9 Hz for acyl chain 
terminal methyls when 47 M C188-SL was added). This suggests not only PA acyl 
chains, but also PC acyl chains, were affected upon EF binding. This indicates that when 
the EF binding occurs, the hydrophobic interaction with the lipid acyl chains comes into 
effect regardless of their head groups.  
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Figure 4-15. Linewidth of phospholipid 1H resonances as a function of the amount of spin 
labeled EF mutant added. To (A) 4 mM d54-DMPC/POPA (1:1) SUV, or (B) 4 mM 
DMPC/POPA (1:1) SUV, EF specifically labeled at Cys148 (open symbols ,) or 
Cys188 (solid symbols ,) was added. Measured linewidths include 1H resonances 
assigned to methylene chains (,) and acyl chain terminal methyl groups (,). 
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Figure 4-16. Linewidth of phospholipid 1H resonances as a function of the amount of spin 
labeled EF added. EF specifically labeled at Cys188 was titrated into SUV of 4 mM 
d54-DMPC/POPA (1:1) (open symbols ,), 4 mM DMPC/POPA (1:1) (solid symbols 
,), or 4 mM POPC (triangles ,). Measured linewidths include 1H resonances 
assigned to methylene chains (,,) and acyl chain terminal methyl groups (,,). 
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4.2.4 Removing basic residues in the EF-hand domain weakens vesicle binding 
The affinities of the EF-hand domain for anionic phospholipids in the absence of 
calcium strongly suggest that basic residues of the EF-hand domain, such as Arg and Lys, 
are important for the interactions with membrane surface. The first pair of EF-hand 
helices, EF1, is rich in basic residues, with 23% of its amino acids being Arg or Lys 
(Fig. 4-17). Additionally, given the positions of the active site of the catalytic domain and 
the calcium binding regions of the C2 domain (141), as well as the topological 
arrangement of the catalytic core of PLC 1 (namely, EF, catalytic and C2 domains), the 
N-terminal lobe of the EF-hand domain, EF1 and EF2, could also be in the proximity of 
the membrane surface when the full-length PLC 1 binds to the membrane (Fig. 4-18). 
To test the importance of Arg or Lys in EF1 and EF2 (Fig. 4-19), mutants with one or 
multiple Arg/Lys substituted with Ala were constructed. To compare these mutants with 
the wild type EF, we performed the centrifugation-filtration vesicle binding assay, first 
using binary vesicles, POPC/DOPA (1:1) SUVs, to which the wild type EF binds 
relatively well (KD = 0.12 mM, from Table 4-1). The binding assay results are listed in 
Table 4-3. Compared to WT, all basic residue mutants showed weaker binding to the 
PC/PA SUVs. KD’s were slightly increased (by ~2-fold) when one Arg or Lys was 
replaced (K163A, K170A, R186A), and the extent to which the KD was increased was 
similar among these single mutants; when multiple Arg/Lys were replaced (e.g. triple 
mutant R182A/K183A/R186A), the KD’s were further increased. Interestingly, once 
R150 and K151 were replaced, further substitution of neighboring lysines with alanines 
(triple mutant R150A/K151A/K154A and quadruple mutant 
R150A/K151A/K154A/K156A) did not result in a further increase in KD.  
107 
 
Figure 4-17. Amino acid sequence (133–297) of EF-hand domain of human PLC 1. 
133 
GSMDQRQKLQ  HWIHSCLRKA  DKNKDNKMSF  KELQNFLKEL 
 
NIQVDDSYAR  KIFRECDHSQ  TDSLEDEEIE  AFYKMLTQRV 
  
EIDRTFAEAA  GPGETLSVDQ  LVTFLQHQQR  EEAAGPALAL 
  
SLIERYEPSE  TAKAQRQMTK  DGFLMYLLSA  DGSAFSLAHR   RVYQD297   
 
 
Figure 4-18. Crystal structure of rat PLC1 (1–132) complexed with calcium (PDB ID: 
1DJI). EF-hand domain is shown in blue, with different shades of blue to indicate EF1–4; 
the catalytic domain is shown in cyan, with active site residues His311 and His356 side 
chains shown as orange sticks; the C2 domain is shown in magenta; calcium ions are 
shown as green spheres. The dotted cylinder indicates where the missing part of EF1 
might be. 
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Figure 4-19. Crystal structure of the EF-hand domain of rat PLC 1 (PDB ID: 1DJI) with 
mutated Arg/Lys residues marked (structural information was not available for residues 
133–157, therefore no marking for R150, K151, K154 or K156). The EF helix pairs have 
the same color-coding as in Fig. 4-18 (EF1–2 at the top and EF3–4 at the bottom). This 
view is obtained by rotating Fig. 4-18 horizontally for approximately 90o (without 
showing the catalytic domain and the C2 domain, which would have been behind the 
EF-hand domain). The structure is indicated with respect to the membrane (assumption 
made from the positions of the active site of the catalytic domain and the calcium binding 
regions of the C2 domain). The dotted cylinder indicates where the missing part of EF1 
might be. 
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Table 4-3. Apparent dissociation constants for EF basic residue mutants binding to 
POPC/DOPA (1:1) SUVs in 20 mM Tris, 0.1 mM EGTA, pH7.5. 
EF constructs Apparent KD (mM)* KD(mutant)/KD(WT) 
WT 0.12  ± 0.02 1.0 
R150A/K151A 0.51 ± 0.04 4.3 
R150A/K151A/K154A 0.41 ± 0.07 3.4 
R150A/K151A/K154A/K156A 0.44 ± 0.06 3.7 
K163A 0.20 ± 0.03 1.7 
K170A 0.27 ± 0.08 2.3 
R186A 0.23 ± 0.06 1.9 
R182A/K183A/R186A 0.35 ± 0.02 2.9 
*This is the total concentration of phospholipids present for half of maximum binding. Errors 
were determined from the hyperbolic fit to the data. 
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In addition to PC and PS, there are other lipids present in the plasma membrane 
inner leaflet in considerable amounts, such as cholesterol (CH), 
phosphatidylethanolamine (PE), sphingomyelin (SM) and phosphatidylinositol (PI). It 
would be interesting to see how the EF interacts with vesicles containing these lipid 
components, and how the mutations in the EF affect the interaction. Therefore we 
adopted the following lipid composition: PE/PC/PS/PI/SM/CH (34.5/10.5/21/4.5/4.5/25), 
which is similar to the plasma membrane inner leaflet (116), in our vesicle binding assays. 
The molar fraction of anionic lipids (PS and PI) is 25.5% in the inner plasma membrane 
mimicking vesicles, compared to a molar fraction of 50% in the binary vesicles. Since the 
EF-hand domain prefers negatively charged membranes, it is not surprising that the 
apparent KD of EF for the inner plasma membrane mimicking vesicles, 0.31 mM 
(Table 4-4), is greater than those for the binary vesicles (Table 4-1). Similar to the 
binding study with binary vesicles, the two triple mutants, R150A/K151A/K154A and 
R182A/K183A/R186A, show weaker binding (2–3 fold increase in KD) to the inner 
plasma membrane mimicking vesicles compared to WT (Table 4-4).   
The largest increase in KD among the mutants we have designed is 4-fold, which 
is not a substantial change in terms of binding. This indicates that other types of forces, 
such as hydrophobic interaction, should also be taken into consideration. 
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Table 4-4. Apparent dissociation constants for EF mutants binding to inner plasma 
membrane mimics a. 
EF constructs Apparent KD (mM) 
b KD(mutant)/KD(WT) 
WT 0.31 ± 0.05 1.0 
R150A/K151A/K154A 1.03 ± 0.19 3.3 
R182A/K183A/R186A 0.81 ± 0.19 2.6 
W144A 1.08 ± 0.36 3.5 
L149A 0.45 ± 0.03 1.5 
F162A 0.31 ± 0.01 1.0 
F168A 1.54 ± 0.34 5.0 
V176A 0.44 ± 0.02 1.4 
Y180A 0.54 ± 0.06 1.7 
F185A 0.46 ± 0.10 1.5 
I201A 0.37 ± 0.03 1.2 
a The SUV composition was PE/PC/PS/PI/sphingomeylin/cholesterol equal to  
34.5/10.5/21/4.5/4.5/25; the buffer was 20 mM Tris, 0.1 mM EGTA, pH7.5. 
b This is the total concentration of phospholipids present for half of maximum binding. 
Errors were determined from the hyperbolic fit to the data. 
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4.2.5 Removing selective hydrophobic residues in the EF-hand domain weakens 
vesicle binding  
In an effort to identify residues important for hydrophobic interaction with 
membranes, we chose a variety of hydrophobic residues (Trp, Phe, Tyr, Val, Ile and Leu) 
in the N-terminal lobe of the EF-hand domain (EF1 and EF2) and separately mutated 
them to Ala. These hydrophobic residues either appear to be on the protein surface in the 
crystal structure (Fig. 4-20), or are within residues 133–157, whose structural information 
is not available. The binding of these mutants to plasma membrane inner leaflet 
mimicking SUVs was measured and the results are listed in Table 4-4. Except for 
W144A and F168A, all the other mutants showed similar affinities for the vesicles as WT 
protein.  
Although we cannot ascertain from the crystal structure whether Trp144 (the only 
Trp in the EF-hand domain) is on the protein surface, or whether it is positioned in an 
orientation that allows close contact with the membranes, we can infer from the 
fluorescence spectrum of the EF-hand domain (Fig. 4-4) that this tryptophan is 
reasonably exposed to solvent (emission wavelength is around 345 nm). In addition, 
vesicles containing PA altered the environment around Trp144 (Fig. 4-7A), suggesting 
that the vesicle binding sites may be close to Trp144, or the binding of the vesicles may 
lead to a conformational change that affects the local environment of Trp144 since there 
is a small red shift in the emission maximum along with the FRET (Fig. 4-9A). 
Furthermore, tryptophan is generally prone to insertion into membranes, and it could very 
well be the case for this particular Trp144. The insertion of Trp144 into membranes 
would assist in anchoring the first EF-hand helices onto the membranes. 
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On the other hand, even though Phe168 appears on the protein surface in the 
crystal structure, it does not have the same orientation as the active site pocket of the 
catalytic domain (Fig. 4-20), and hence not likely to be in close contact of, or insert into 
the membrane surface when it is in the full-length PLC 1. The weaker binding shown by 
F168A (which is a mutated single domain) may very well be an artifact, caused by the 
lack of positioning restrictions imposed by other domains. 
 
 
Figure 4-20. Crystal structure of rat PLC 1 (PDB ID: 1DJI) with mutated hydrophobic 
residues marked as yellow sticks (structural information was not available for residues 
133–157, therefore no marking for W144 or L149). The view is presumably looking 
down from the membrane surface. EF-hand domain is shown in blue; the catalytic 
domain is shown in cyan, with active site residues His311 and His356 side chains shown 
as orange sticks; the C2 domain is shown in magenta; calcium ions are shown as green 
spheres. The dotted cylinder indicates where the missing part of EF1 (including W144 
and L149) might be.  
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4.3 Discussion 
Previous reports identified the EF-hand domain of PLC 1 as a lipid interacting 
domain, highlighting its interaction with fatty acid (arachidonic acid in particular) 
(103,136). In my work, it is found that the isolated EF-hand domain binds to arachidonic 
acid only when it is partially oxidized (Section 4.2.2). So the interplay of free fatty acids 
such as arachidonic acid and PLC 1 may not occur in normal cells. Nonetheless, the 
hydrophobic interaction between the oxidized arachidonic acid and the protein remains 
plausible, with the additional possibility that electrostatic interaction between the lipid 
and the protein also plays a role since oxidized arachidonic acid is likely to be more 
negatively charged. Anionic phospholipids thus become the next potential ligand for the 
EF-hand domain. Subsequently, the selective affinity of the EF-hand domain for anionic 
phospholipids is demonstrated with the centrifugation-filtration binding assay and the 1H 
NMR assay (Section 4.2.3.3 and Section 4.2.3.4). 
Although EF-hand motifs are often associated with Ca2+ binding, there is no 
experimental evidence to show that this is actually the case with PLC 1. While the loop 
regions of EF3 and EF4 do not have typical calcium ligands, EF1 and EF2 do (85). 
However, the mutations of these putative calcium binding residues (Asp153, Asp157, 
Glu164) do not affect enzyme activity (135), suggesting that EF binding of calcium, even 
if it occurs, is not required in the enzymatic reaction. In fact, in all the known crystal 
structures of PLC 1, no calcium ion is found associated with the EF-hand domain, even 
though the enzyme is soaked in calcium or its analogs (85,139–141). Likewise, EF-hand 
domains of PLC 2 (82,87) and 3 (88), the only other PLC EF-hand domains with 
known structures, are not found to be associated with calcium. In our binding assays, the 
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isolated EF-hand domain can bind to vesicles of various compositions containing anionic 
phospholipid without Ca2+. Curiously, the first EF-hand motif of the PLC 1 is replete 
with cationic residues, which would exert similar electrostatic force on negatively 
charged lipids as Ca2+-bound residues would. Sequence comparison of several members 
from the PLC,  and  subfamilies reveals that only 13 amino acids are identical or 
conserved outside the highly conserved X/Y catalytic domain and C2 domain, and that all 
of them are located in the EF-hand domain (143). Among these conserved residues are 
Lys151 and Lys170 of PLC 1 (the rest include 9 hydrophobic residues, 1 Gln, and 
1 Glu/Asp). Taken together, the cationic residues in the EF-hand domain of PLC , 
especially the well conserved K151 and K170, may play an important role in the 
interaction of the EF-hand domain with membranes containing anionic lipids. 
It is possible that the EF-hand domain is initially attracted to the anionic 
component of the membrane through electrostatic interaction (hence no binding occurs 
without anionic lipids). But once the protein is in the proximity of or inserted into the 
membranes, the hydrophobic interaction with the lipid acyl chains also comes into effect 
regardless of the types of charge their head groups carry. Experimentally, removing key 
basic residues or hydrophobic residues indeed weakens the EF binding to vesicles, 
although not to substantial extents (Section 4.2.4 and Section 4.2.5). This is not surprising, 
given that other domains of the PLC 1, PH domain in particular, have been shown to 
play major roles in membrane tethering (79,80,144,145). However, the fact that the PLC 
1 loses enzymatic activity with membrane substrate when the EF-hand domain is 
deleted (134,135) argues that the EF-hand domain carries significance—even if not in 
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tight membrane association—in the regulation of the enzymatic activity of the PLC1, 
which will be addressed in the next chapter.  
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Chapter 5  
Role of EF-hand Domain in Regulating Mammalian PLC 1 Activity 
5.1 Introduction 
Many aspects of the catalytic mechanism of PLC 1, such as its calcium 
dependence, substrate specificity, reaction pathway, and membrane attachment, have 
been elucidated. The hydrolysis carried out by PLC 1, like other eukaryotic PLCs, is 
strictly dependent on calcium as a cofactor (61,62,146). At physiological calcium 
concentrations (0.01–10 M) the substrate preference of PLC 1 for phosphoinositides is 
PIP2 > PI(4)P >> PI (62). In the crystal structure of a PLC 1/Ca
2+/IP3 complex (85), a 
6-coordinated calcium ion is found at the bottom of the active site, ligating to the axial 
2-hydroxyl group of IP3 (the head group of its substrate PIP2) and the highly conserved 
residues in the catalytic domain (Asn312, Glu341, Asp343 and Glu390), consistent with 
the strict calcium requirement for enzyme activity. In addition, all chemical groups of the 
IP3 molecule (except for the 6-hydroxyl group) are stereospecifically recognized by an 
extensive hydrogen-bonding network and specific charge-charge interactions. For 
example, the 1-phosphoryl group of IP3 is engaged in hydrogen bonds with His311 and 
His356 (Fig. 4-18, Fig. 4-20), residues essential for catalytic activity (147,148); the axial 
2-hydroxyl group of IP3 not only directly coordinates with the catalytic calcium ion, but 
also forms hydrogen bonds to Asn312, Glu341 and Glu390; the equatorial 3-hydroxyl 
group of IP3 forms hydrogen bonds to residues at the bottom of the active site, leaving 
insufficient space for phosphorylation at this 3-hydroxyl group, justifying 
3-phosphoinositides as poor substrates (149); the 4- and 5-phosphoryl groups of IP3 form 
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various salt bridges to PLC 1 residues, offering an explanation for the observed 
substrate preference of PIP2 > PIP >> PI. Combining structural and kinetic data 
(85,140,150), a sequential mechanism involving general acid/general base catalysis has 
been proposed (Fig. 5-1). First, in the phosphotransfer step, the axial 2-hydroxyl group of 
PIP2 acts as a nucleophile to attack the phosphorus, leading to the formation of a cyclic 
phosphodiester; second, in the phosphorolysis step, the cyclic intermediate is hydrolyzed 
to yield acyclic IP3.  
 
Figure 5-1. Proposed reaction mechanism for PLC 1. The putative general acid is 
His356. The identity of the general base is not conclusive. Candidates include His311, 
Glu341 and Glu390. See references 85 and 140 for detailed discussion. 
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In addition to its catalytic domain, the PH domain of PLC 1 also binds to the 
substrate PIP2 and its head group IP3. The isolated PH domain has been shown to bind 
tightly to both IP3 (Kd = 210 nM) and PIP2-containing vesicles (Kd = 1.7 M) with 
specificity (80). The binding site for IP3 has been identified by structural study. As shown 
in Fig. 5-2, the PLC 1 PH domain exhibits a  sandwich structure with a C-terminal  
helix on one side (132). At the opposite side of the C-terminal  helix, there is a 
distinctive positively charged region on the surface of the domain, in the center of which 
is the IP3 binding site. Some key residues in the binding site have been verified in a 
kinetic study (145). Furthermore, the PLC 1 PH domain is required for membrane 
attachment in vitro (79), and the binding of the PH domain to PIP2 enhances PLC 
hydrolysis (145). Interestingly, deleting the PH domain from PLC 1 does not affect the 
enzyme activity toward PIP2 in micelles; when the substrates are presented in 
reconstructed cell membranes, however, the PLC activity is greatly decreased (151). This 
suggests the PH domain regulates enzyme activity by interacting with cellular 
membranes, not by directly affecting the active site. On the other hand, besides the active 
site in the catalytic domain, binding of calcium ion(s) or its analogs has also been 
observed in the PLC 1 C2 domain, although with varying numbers of bound metal ions. 
Among the four putative metal ion binding sites in the C2 domain (85), two have been 
seen occupied by calcium (Fig. 4-18, Fig. 4-20), while three can bind to lanthanum (141). 
Structural data suggest calcium-induced conformational changes in the C2 domain may 
allow phospholipid binding (139). Indeed, binding studies show that a PLC1-Ca2+-PS 
ternary complex forms through the C2 domain, which enhances membrane targeting and 
consequently enzyme activity (133,152). Taken together, a two-step mechanism for the 
120 
 
interaction of PLC 1 with membranes has been proposed (85): the PH domain tethers 
the enzyme to the membrane by specific binding to PIP2, and the C2 domain fixes the 
catalytic domain in a productive orientation relative to the membrane. However, the role 
of the EF-hand domain plays in the regulation of PLC activity is still not clearly 
understood. 
In Chapter 4, using site-directed mutagenesis, we have identified several residues 
in the EF-hand domain that contributed to the interfacial binding of this isolated domain. 
In this work we examined how these interfacial interactions of the EF-hand domain 
affected the PLC activity of the full-length enzyme. 
 
Figure 5-2. Crystal structure of the isolated PLC 1 PH domain complexed with IP3 (PDB 
ID: 1MAI). PH domain is shown in gold. The N- and C-terminus of the PH domain is 
indicated in blue and red, respectively. The IP3 molecule is shown as sticks.  
 
121 
 
5.2 Results 
5.2.1 Mutations in the EF-hand domain compromise enzymatic activity  
We chose two EF mutants, single mutant W144A and double mutant 
R150A/K151A (which showed weaker binding to model membranes), and constructed 
the same mutations in the full-length PLC 1. The effects of these mutations on PLC 
hydrolysis activity were examined. The specific activities of PLC 1 wild type and 
mutants were measured using PI as substrate, embedded in vesicles of various 
compositions and sizes (LUV or SUV), or with varied concentrations of calcium (0.5 or 
0.1 mM). Although PI is not the most preferred substrate for PLC 1, it is much less 
costly, allowing us to use the amounts necessary for the 31P NMR activity assays. The 
vesicle compositions were designed based on what was used in the binding assays (binary 
vesicles and plasma membrane mimicking vesicles), with some modification. For plasma 
membrane composition vesicles, we increased the molar fraction of PI (from 4.5% to 
25.5% or 12.75%) while keeping the molar fraction of total anionic lipids constant 
(25.5%), so that the hydrolysis products of PI can be accurately measured by 31P NMR 
within a reasonable time frame. In all our assays (see Section 2.2.9 for experimental 
procedures), both the intermediate product myo-inositol 1,2-(cyclic)-phosphate (cIP) and 
the final product inositol-1-phosphate (I-1-P) were observed. This has been seen before 
for this enzyme acting on PI (153). As explained in the proposed catalytic mechanism 
(Fig. 5-1), the PLC 1 does not proceed by covalent catalysis, rather cIP is formed as an 
intermediate, and it is either released into solution or attacked by H2O with the release of 
I-1-P. The specific activities were calculated as the sum of both products and listed in 
Table 5-1.  
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Here we used the LUV system (total lipid concentration = 10 mM) composed of 
PI/PE/PC/SM/CH (25.5/34.5/10.5/4.5/25) in the presence of 0.5 mM Ca2+ as the 
“standard system”, to which all the other vesicle systems are compared. First, the effect 
of calcium was examined. As shown in Fig. 5-3A, when the calcium concentration was 
decreased from 0.5 mM to 0.1 mM, PLC WT and mutants all showed lower activities, the 
decreases being 3.6-, 4.6-, and 5.9-fold for WT, W144A, and R150A/K151A, 
respectively. This is consistent with the important role calcium plays in PLC 1 catalyzed 
hydrolysis of substrate. Furthermore, it suggests these mutations in the EF-hand domain 
did not reduce the enzyme’s sensitivity towards calcium. Next, the effect of vesicle size 
was examined. With the same lipid composition [PI/PE/PC/SM/CH 
(25.5/34.5/10.5/4.5/25)], the WT and the two mutant enzymes preferred SUVs to LUVs 
(Fig. 5-3B), indicating that PLC hydrolysis can be enhanced by membrane curvature and 
possibly surface defects. Interestingly, while the WT and W144A enzymes showed 
similar extents to which the SUVs were preferred (a 3.3-fold and a 3.2-fold increase in 
activity comparing SUVs to LUV were observed for WT and W144A, respectively), the 
double mutant R150A/K151A seemed to have a slightly greater preference for SUVs 
(activity increase was 4.5-fold). Lastly, the effects of substrate concentration and anionic 
lipid component in the vesicles were examined. As shown in Fig. 5-3C, the specific 
activities of WT were 18.4, 18.6, and 18.6 mol.min−1.mg−1, with 10 mM 
PI/PE/PC/SM/CH (25.5/34.5/10.5/4.5/25) LUVs (denoted as “LUV-1”), 10 mM 
PI/PS/PE/PC/SM/CH (12.75/12.75/34.5/10.5/4.5/25) LUVs (“LUV-2”), and 5 mM PI/PC 
(50/50) LUVs (“LUV-3”), respectively. Therefore it appeared that the activity of WT was 
unaffected by the changes in the bulk concentration of PI, the molar ratio (that is, the 
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surface concentration) of PI, or the total molar ratio of anionic lipids under these 
conditions. However, the effects of these changes in the membrane composition had on 
the activity of the two mutants seemed to vary. Comparing the specific activity of either 
mutant between LUV-1 and LUV-2, taking into consideration the standard deviations, I 
found that both mutants were unaffected by the two-fold decrease in the surface 
concentration of PI. On the other hand, comparing LUV-3 with LUV-1, the specific 
activity of R150A/K151A in particular, decreased 3-fold even though the surface 
concentration of the substrate (50 mol%) was actually larger than that of LUV-1 
(25.5 mol%) (the bulk PI concentration was about the same for both samples). The lipid 
components missing from LUV-3 included sphingomyelin and cholesterol, which are 
thought to form raft-like domains in the presence of a fluid PC-matrix (154), and 
biological membranes with rafts often have GPI-linked proteins associated with them. 
The lower activity towards PI in LUV-3 compared to LUV-1 could suggest that residues 
Arg150 and Lys151 are instrumental for the recognition of raft-like domains — not in 
terms of binding to the vesicles but in either correct binding of substrate or release of 
product back into the membrane.  
It should be emphasized that across all the vesicle systems we examined (Fig. 5-3, 
Table 5-1) the specific activities of W144A and R150A/K151A were generally lower 
than that of the WT, with R150A/K151A losing more activity than W144A. In the 
complex LUVs, the decreased activity for both mutants would be consistent with an 
increased two-dimensional Km for substrate in terms of mole fraction PI. In the type of 
kinetic analyses used with soluble enzymes acting on substrates in vesicles (155,156), 
this is not the enzyme/vesicle binding step, but access of the substrate to the active site or 
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potentially product release. This indicates that the residues Trp144, Arg150 and Lys151 
may not only contribute to the binding of the EF-hand domain to membranes, but also 
play an indirect role in modulating the hydrolysis activity of the full-length enzyme. 
 
Table 5-1. Hydrolysis of PI in lipid vesicles by the wild type and mutant PLC 1. 
Vesicle composition 
Concentration 
of calcium 
(mM) 
Type of PLC 1 
PI hydrolysis* 
(mol.min−1.mg−1) 
10 mM PI/PE/PC/SM/CH 
(25.5/34.5/10.5/4.5/25) LUV 
0.5 
WT 18.4 ± 4.5 
W144A 12.6 ± 3.5 
K150A/K151A 5.9 ± 1.5 
10 mM PI/PE/PC/SM/CH 
(25.5/34.5/10.5/4.5/25) LUV 
0.1 
WT 5.1 ± 1.0 
W144A 2.8 ± 0.3 
K150A/K151A 1.0 ± 0.2 
10 mM PI/PE/PC/SM/CH 
(25.5/34.5/10.5/4.5/25) SUV 
0.5 
WT 60.5 ± 0.1 
W144A 40.5 ± 7.2 
K150A/K151A 26.7 ± 3.2 
10 mM PI/PS/PE/PC/SM/CH 
(12.75/12.75/34.5/10.5/4.5/25) 
LUV 
0.5 
WT 18.6 ± 2.7 
W144A 8.6 ± 2.0 
K150A/K151A 4.6 ± 0.3 
5 mM PI/PC (50/50) LUVs 0.5 
WT 18.6 ± 7.9 
W144A 7.6 ± 0.9 
K150A/K151A 1.9 ± 0.1 
* The errors are determined by the standard deviation of at least two repeats. 
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Figure 5-3. Specific activities of PLC 1 WT (solid), W144A (diagonal lines) and 
R150A/K151A (horizontal lines) toward PI in vesicles made to mimic the inner leaflet of 
mammalian plasma membranes: (A) 10 mM PI/PE/PC/SM/CH (25.5/34.5/10.5/4.5/25) 
LUVs in the presence of 0.5 mM or 0.1 mM Ca2+; (B) LUV or SUV of the same vesicle 
composition (PI/PE/PC/SM/CH=25.5/34.5/10.5/4.5/25) and the same amount (0.5 mM) 
of Ca2+; (C) LUVs with various bulk PI concentrations, molar ratio of PI, and molar ratio 
of anionic lipids in the presence of 0.5mM Ca2+. The error bars indicate the standard 
deviation of at least two repeats. 
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5.2.2 Presence of PIP2 partially rescues the hydrolysis activities of EF-domain 
mutants towards PI 
Since the total lipid concentration in the vesicles used in the activity assays (10 or 
5 mM) were well above the KD for the EF-hand domain partitioning onto the vesicles, it 
is reasonable to assume the full-length PLC to be completely bound at such 
concentrations. Preliminary binding data from Dr. Su Guo also suggested that with this 
amount of lipid and 25 mol% anionic phospholipid, all the PLC 1 should be bound (157). 
This should eliminate any effects the mutations may have on the enzyme activity due to 
differences in bulk binding. The fact that the mutants exhibited decreased activities in 
several vesicle systems suggests that factors other than binding are at play. To further 
examine this hypothesis, we measured the specific activities of PLC 1 at a much lower 
vesicle concentration, with a total lipid concentration of 0.5 mM. With the same vesicle 
composition PI/PE/PC/SM/CH (25.5/34.5/10.5/4.5/25), the PLC 1 enzymes showed 
much lower activities when the total lipid concentration was reduced from 10 mM to 
0.5 mM, likely due to a high Km for PI that reflects binding of that lipid in the active site. 
The specific activity for the WT enzyme was 1.1 mol.min−1.mg−1, of which W144A 
retained 54% while R150A/K151A retained 23% (Fig. 5-4A, Table 5-2). In comparison, 
with LUVs composed of 10 mM lipids, W144A and R150A/K151A, respectively, 
retained 69% and 32% of the activity of the WT (Fig. 5-3, “LUV-1”). At lower vesicle 
concentration there might be differences in the percentage of enzyme bound to the 
vesicles, thus the lower retention of WT activity by the mutants at low vesicle 
concentration indicates that the differences in bulk binding between the WT and mutant 
enzymes could still make a difference in enzyme activities. To this end, 1 mol% PIP2 
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(5 M) was added to the vesicle composition, which would presumably lead to complete 
binding of the PLC enzymes even at the low vesicle concentration, since the isolated PH 
domain is reported to bind to PIP2-containing vesicles with a Kd of 1.7 M (80). In 
addition to PI, PIP2 was also hydrolyzed, producing a single product IP3, with a 
hydrolysis percentage generally over 40%, while less than 20% of PI was hydrolyzed. 
The specific activities reported here are limited to those toward PI. Consistent with 
previous studies (145), the incorporation of PIP2 into the membranes activated PLC 
hydrolysis towards PI: the increase was 3.3-fold, 4.3-fold, and 5.5-fold for WT, W144A 
and R150A/R151A, respectively. Furthermore, the presence of PIP2 appeared to enhance 
the activity retention of the mutants: W144A exhibited 70% and R150A/K151A 
exhibited 40% of the WT activity (Fig. 5-4B, Table 5-2). Thus, PIP2 must aid the enzyme 
in attaching to and adopting a productive orientation on the membrane surface. However, 
even with a PIP2 anchor in the PH domain, the loss of the two cationic residues in EF1 
significantly lowers the enzyme specific activity.  
 
Table 5-2. Hydrolysis of PI in lipid vesicles in the absence and presence of PIP2 by the 
wild type and mutant PLC 1. 
Vesicle composition 
Concentration 
of calcium 
(mM) 
Type of PLC 1 
PI hydrolysis* 
(mol.min−1.mg−1) 
0.5 mM 
PI/PE/PC/SM/CH 
(25.5/34.5/10.5/4.5/25)  
LUV 
0.5 
WT 1.1 ± 0.2 
W144A 0.58 ± 0.15 
K150A/K151A 0.25 ± 0.07 
0.5 mM 
PI/PIP2/PE/PC/SM/CH 
(25.5/1/33.5/10.5/4.5/25) 
LUV 
0.5 
WT 3.5 ± 0.7 
W144A 2.5 ± 0.1 
K150A/K151A 1.4 ± 0.1 
* The errors are determined by the standard deviation of at least three repeats.   
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Figure 5-4. Specific activities of PLC 1 WT (solid), W144A (diagonal lines) and 
R150A/K151A (horizontal lines) toward PI in inner leaflet composition LUVS in the 
absence or presence of 1 mol% PIP2: LUVs with composition (A) 0.5 mM 
PI/PE/PC/SM/CH (25.5/34.5/10.5/4.5/25) or (B) 0.5 mM PI/PIP2/PE/PC/SM/CH 
(25.5/1/33.5/10.5/4.5/25) in the presence of 0.5 mM Ca2+. The error bars indicate the 
standard deviation of at least three repeats. 
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5.3 Discussion 
Although much of the relationship between the structural features of the 
components of PLC 1 and their contributions to the activity regulation has been 
scrutinized, the role of the EF-hand domain remains elusive. Here we identify three 
residues in the EF-hand domain of PLC 1, Trp144, Arg150, and Lys151, that are 
important for the enzyme to express maximal hydrolysis activity. Through binding 
studies of the isolated EF-hand domain, we find the domain may play a role in membrane 
binding, though it is not likely a major role, since both the PH domain, via PIP2, and the 
C2 domain, via Ca2+/PS interactions, have much tighter interactions with bilayers. Thus, 
it is more likely the EF-hand domain of PLC 1 is relevant to how the catalytic domain is 
oriented, how substrate finds its way into the active site, or how products are released. 
Structural studies show that PLC 1 has a strikingly rigid core composed of the 
C-terminal half of the EF-hand domain, the catalytic domain (except for residues 445–
485 and 509–514), and the C2 domain (139). In contrast, the first half of the EF-hand 
domain is quite flexible, as evidenced by the poor ordering of this region in the crystal 
structures. Therefore, this region may serve as a flexible bridge between the PH domain 
and the rigid core of the enzyme, which, upon association with membrane lipids, primes 
the active site for substrate access. Interestingly, anionic phospholipids PA, PG and PS 
can greatly enhance PLC 1 hydrolysis toward PI (5–15-fold increase over SUVs 
containing PC only) (145); in addition, PS and PA have been found to stimulate PLC 1 
hydrolysis of PIP2 by a factor of 20 and 4, respectively (133). While it is believed that PS 
is involved in enzyme binding (via the C2 domain) in a Ca2+ dependent manner, PA does 
not participate in Ca2+-mediated binding of the enzyme (133). In our binding studies, the 
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isolated EF-hand domain binds to both PA and PS with comparable affinity, and to PG 
with a slightly weaker affinity, all independent of Ca2+. Thus, the stimulation of PLC 1 
activity by PA may involve the interaction between PA and the EF-hand domain. Our 
activity data (Fig. 5-3C) from membranes with and without sphingomyelin/cholesterol 
(which are believed to involve in the formation of raft-like domains) suggest that residues 
Arg150 and Lys151 can contribute to the recognition of raft-like domains where the 
substrates of the enzyme may cluster. It is therefore likely that the first half of the 
EF-hand domain provides a site (in addition to the PH domain and the C2 domain) for 
activity regulation by the lipid components in the membrane. Alternatively, the 
N-terminal lobe of the EF-hand domain could modulate the enzyme activity by affecting 
reaction product release. A previous study indicates that IP3 inhibits the stimulatory effect 
of PIP2 on the hydrolysis of PI by competing with PIP2 for the binding of the PH domain 
of PLC 1 (145). The EF-hand domain may in turn serve as a flexible bridge between the 
PH domain and the catalytic domain that facilitates the release of this soluble, highly 
negatively charged product from the active site as directed by the PH domain. It would be 
interesting to see how the mutations in the EF-hand domain would affect PLC 1 
hydrolysis in a mutant enzyme without the PH domain. 
In addition to the N-terminal half of the EF-hand domain, there is another 
extended region of PLC 1 that lacks interpretable electron density in crystallographic 
studies, namely residues 445–485 (85,139). This region, termed X/Y linker, connects the 
catalytic X and Y domains. A deletion mutant lacking residues 461–471 
(461DEVEAAEMEDE471) was constructed by Dr. Su Guo. The deleted segment is located 
at the center of the X/Y linker and clustered with negatively charged residues. Dr. Guo’s 
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results indicate that these 11 residues in the X/Y linker play an autoinhibitory role in 
membrane binding and affect enzyme activity by regulating the access of 
phosphoinositide substrates to the active site (157). This is supported by another study in 
which the deletion of 44 residues in the X/Y linker of PLC 1 resulted in up to a 10-fold 
increase in PLC activity compared to the wild-type in transfection experiments (87). In 
fact, the same study also shows that the X/Y linkers in PLC  and  isozymes play a 
similar autoinhibitory role. In particular, for PLC 2, the disordered region of the X/Y 
linker in its crystal structure serves as the major autoinhibitory determinant while the 
ordered region appears to fine-tune access to the active site. Interestingly, the calcium 
binding regions in the C2 domain of PLC 1 are also highly flexible. In fact, there is a 
lack of interpretable density for these regions in the crystal structure when metal ions are 
absent. It is with the binding of the metal ions that these regions become defined (139). 
Therefore, these highly flexible regions, including the N-terminal half of the EF-hand 
domain, while difficult to have their functions determined with crystallographic studies, 
may play important modulatory roles in ligand binding as well as enzyme activity.  
Currently, the only other crystal structures of PLC isozymes that have been solved 
are those of PLC 2 and 3 complexed with a regulatory protein (82,87,88), in which the 
EF-hand domains are fully defined. While the EF-hand domains of these -isozymes 
have not been implicated in membrane association, the topological arrangement of the 
PLC domains (PH, EF-hand, catalytic X/Y, and C2) as well as the regulatory protein in 
the complex (Rac1 for PLC 2 and Gq for PLC 3) with respect to the interface 
suggests that the N-terminal lobe of the EF-hand domain in these PLCs could be in the 
proximity of the membrane surface when the enzymesare bound to the membranes. 
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Indeed, in both PLC  structures (Fig. 5-5), there is a cluster of Arg and Lys residues in 
the N-terminal lobe of the EF-hand domain appearing to point towards the assumed 
interface in a similar fashion as PLC 1 (Fig. 4-19). On the other hand, PLC , the only 
isoform in the PLC family lacking a PH domain, is specifically expressed in sperm and 
known to induce intracellular Ca2+ oscillations and subsequently activate oocyte 
fertilization (73). Interestingly, a splicing variant of PLC lacking 110 residues from the 
N-terminus corresponding to the EF1–3 but identical to PLC  in EF4 and the succeeding 
region failed to elicit a Ca2+ spike (101). This indicates that the EF1–3 region is important 
for PLC  to induce Ca2+ oscillations. PLC  shares the closest homology with PLC 1 
(158). Particularly, Arg182, Lys183 and Arg186 of PLC 1, which have been shown to 
contribute to the binding of vesicles containing anionic lipids in our study (Table 4-3, 
Table 4-4), are conserved in PLC  (Fig. 5-6A). Using regions rich in basic side chains 
for electrostatic orientation of a protein to acidic membranes may be a common 
mechanism for peripheral proteins. For example, one of the two major human PLC  
isoforms (87) has been reported to anchor to the membrane via its basic cluster in the 
X/Y linker (159). Furthermore, sequence comparison within the PLC  subfamily 
(Fig. 5-6B) reveals that Trp144 and Lys151 of PLC 1 (which have been shown to 
contribute to vesicle binding [Table 4-3, Table 4-4] and enzyme activity [Table 5-1, 
Table 5-2]) are also conserved. Taken together, we propose that the N-terminal lobe of 
the EF-domain of PLCs serves a common function to facilitate proper membrane 
association. 
 
134 
 
Figure 5-5. Crystal structures of (A) PLC 2/Rac1 complex (PDB ID: 2FJU) and (B) 
PLC 3/Gq complex (PDB ID: 3OHM). PH domain of PLC  isozymes is shown in 
cyan, EF-hand domain is shown in magenta, the catalytic domain is shown in orange, the 
C2 domain is shown in green; the PLC-bound calcium ion is shown as blue sphere. The 
complexed Rac1 and Gq are shown in grey; Rac1-bound GTP analog, Gq-bound GDP 
and AlF4
− are shown as sticks; Rac1- and Gq-bound magnesium ions are shown as 
yellow spheres. The structures are indicated with respect to the membrane (see references 
82 and 88). Arg and Lys residues in the N-terminal lobe of the EF-hand domain 
appearing to point towards the interface (Lys168, Arg178, Lys179, Arg180, Lys192 and 
Lys194 of PLC 2; Lys173, Lys177, Lys183, Lys184, Arg185, and Arg199 of PLC 3) 
are highlighted as sticks.  
135 
 
 
 
 
A 
B 
136 
 
Figure 5-6. Sequence alignments of the EF-hand domain of PLC isozymes, highlighting 
the conserved residues hypothesized to be important for membrane association. (A) 
Comparison of PLC 1 and PLC  from Rattus norvegicus. (B) Comparison of PLC 1, 
3, and 4 from Homo sapiens. 
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Chapter 6 Future Directions 
The work in this thesis is aimed at understanding the membrane association 
mechanism of two types of calcium-dependent, multi-domain mammalian peripheral 
proteins, namely the pulmonary collectins and the phosphoinositide-specific 
phospholipase C 1, and how their interactions with membranes dictate the functions of 
these proteins. Two binding assays, a modified centrifugation-filtration vesicle binding 
assay allowing fast determination of affinities and 1H NMR assay utilizing mixed vesicles 
of proteo/deuterated lipids, have been developed. While the former was used to assess the 
bulk partitioning of the isolated EF-hand domain of PLC 1 onto vesicles, the latter shed 
light on membrane dynamics in the absence and presence of bound proteins. These two 
binding assays can be extended to a wide range of proteins (or isolated single domains of 
multi-domain proteins) that bind to membranes with moderate binding affinity (lipids in 
the sub-millimolar range).  
In addition, when studying the interactions of calcium-dependent proteins with 
acidic membranes, maintaining membrane stability is often challenging because calcium 
can cause fusion of acidic membranes. We addressed this technical problem by preparing 
vesicles containing anionic lipids in the presence of the calcium (instead of adding 
calcium after the vesicles were formed), so the calcium was on both sides of the vesicles. 
This preparation method proves to enhance the stability of the vesicles and is useful for 
other systems requiring the presence of both calcium and acidic membranes. 
The results of phospholipid membrane binding studies of SP-A and SP-D have 
shown that the two pulmonary collectins have distinctive preferences for lung surfactant 
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lipids. Presumably, in the alveolar space, these collectins are present on the air/water 
interface or the surface of tubular myelin, patrolling for invading pathogens. It would be 
interesting to probe the mechanisms by which these proteins transfer from the membrane 
surface to the carbohydrate-rich pathogen surfaces. Competition assays with various 
carbohydrates such as mannose and glucose monitored by 1H NMR would likely provide 
more information in this regard.  
Based on the results of vesicle binding and catalytic activity studies of the PLC 1, 
we proposed a common role for the N-terminal lobe of the EF-domain of PLCs in 
facilitating proper membrane association via electrostatic interactions with a cluster of 
basic residues and hydrophobic interaction with a conserved tryptophan residue that may 
be unique to the PLC  subfamily. In Section 5.3, I have suggested a plethora of residues 
in the PLC , , and  isozymes that potentially serve the same auxiliary function as 
Trp144, Arg150 and Lys151 of PLC 1. Determining the effects of the mutations of these 
residues on PLC activity will further improve our understanding of the role of the PLC 
EF-hand domain.  
Moreover, the data from the PLC activity assays using the plasma membrane 
mimicking vesicles indicated that the presence of lipid components such as 
sphingomyelin and cholesterol can affect the enzyme activity. In biological membranes, 
the formation of raft-like domains are thought to involve the presence of sphingomyelin 
and cholesterol in a fluid PC-matrix, and are often associated with GPI-linked proteins. 
Therefore the data gathered from these plasma membrane mimics may bear biological 
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significance. Analysis of enzyme kinetics of the EF-hand mutants with these vesicle 
systems will likely support our interpretation on the function of the EF-hand domain. 
Finally, we suggested the EF-hand domain may affect the access of the substrate 
to the active site or product release. There are other regions in the PLC enzyme that have 
been shown to affect substrate access. For example, the studies of the X/Y linker in the 
catalytic domain have revealed that this region modulates PLC activity by constitutively 
occluding the active site; on the other hand, the PH domain of PLC 1 enhances access to 
the PIP2 substrate by specifically anchoring to the membrane surfaces that contains PIP2. 
It would be interesting to see if the EF-hand domain works in tandem with either of these 
two regions. To do so, the EF-hand domain mutations should be combined with the 
deletion of the PH domain or the X/Y linker, and the membrane binding profiles as well 
as enzyme activities of these constructs should be determined. The results of these 
experiments will help us better understand how the PLC enzymes orchestrate its 
structural components in order to carry out the cellular functions.  
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Appendix 
I. Synthesis of labeled lipids for NMR studies 
Field-cycling NMR has been demonstrated to be a very useful method for studying 
the motions of phospholipids in membranes (160–162). While field-cycling 31P NMR 
works well with unlabeled phospholipids, 13C NMR requires 13C-enriched phospholipids. 
In addition, in 31P NMR, protons and deuterons in the vicinity of the phosphorus nuclei 
have different effects on relaxation. Therefore, deuterated phospholipids, in comparison 
to their proteo counterparts, could shed light on the relaxation mechanism of the 
phospholipids in the membranes. Previously, I synthesized sn-2 carbonyl 13C-labeled 
phosphatidylcholines by acylation of 1-palmitoyl-phosphatidylcholine with either 
[1-13C]-oleic acid or [1-13C]-palmitic acid, as a probe in 13C field cycling NMR studies 
(163). To extend our pool of phospholipid probes for NMR studies, several 13C or 2H 
labeled phospholipid molecules have been synthesized from commercially available 
materials by combining traditional organic synthesis and enzyme catalysis. 
I.i. Synthesis of d3-phosphatidylmethanol 
The d3-phosphatidylmethanol (d3-PMe) containing a deuterated methoxy group 
was prepared by transphosphatidylation of DOPC with d4-methanol following a 
published protocol (164). A solution (8.4 ml) of 100 mg dried DOPC in 25 mM HEPES, 
pH 6.5, containing 2,000 units of phospholipase D (PLD) from Streptomyces sp. (Enzo 
Life Sciences) was mixed with 3.6 ml of d4-methanol (Cambridge Isotope Laboratories, 
Inc.) and stirred for 4 hours at room temperature. Another aliquot of PLD (2,000 units) 
was then added and the reaction mixture incubated overnight. A 31P NMR spectrum 
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showed that essentially all the PC was converted to PMe. The product was extracted with 
CHCl3/CH3OH (2:1, v/v) and incorporation of deuterium was confirmed by a 
1H 
spectrum showing a very large (but not complete) reduction in the methoxy protons. This 
was confirmed by mass spectrometry (m/z calculated for C40H71D3O8P [M – Na
+] 
716.9607, found 716.5298). 
I.ii. Synthesis of 13C=O (sn-1) labeled phosphatidylcholine 
The 13C=O (sn-1) POPC was synthesized in three steps (Fig. A-1). In the first step, 
at room temperature, 5.2 mmol N,N’-dicyclohexylcarbodiimide (DCC, Sigma-Aldrich 
Chemical Co.) was added to a solution of 3.5 mmol [1-13C]-palmitic acid (Cambridge 
Isotope Laboratories, Inc.) in 20 ml anhydrous CHCl3 with stirring. The activation of the 
fatty acid was allowed to go on for 30 min before adding 0.86 mmol sn-glycerol-3-
phosphocholine 1:1 CdCl2 adduct (Sigma-Aldrich Chemical Co.) and 1.7 mmol 
4-(dimethylamino)pyridine (DMAP, Sigma-Aldrich Chemical Co.) into the reaction 
mixture, which was then stirred at 37oC for 7 days. The reaction mixture was filtered and 
the filtrate which contained the crude product was purified on silica gel column with step 
gradient elution (sequential eluents: CHCl3; CH3OH/CHCl3, 15:85, v/v; CH3OH/CHCl3, 
40:60, v/v). The fractions collected from the column were characterized by thin layer 
chromatography with a developing solvent system of choloroform:methanol:water 
(65:25:4, by volume). 
In the second step, 200 mg 13C=O (sn-1, sn-2) DPPC from the first step was 
mixed with 9 ml diethyl ether, 1 ml methanol, 0.2 ml water, 0.2 ml phospholipase A2 
(PLA2) from honey bee venom (Sigma-Aldrich Chemical Co.) (1mg/ml, in 100 mM Tris, 
pH 7.5), 80 l 100 mM CaCl2, and stirred at room temperature for 2.5 h. Another aliquot 
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of PLA2 (0.2 mg) was then added and the reaction mixture was stirred for another 3 h. 
After the removal of the organic solvent, the reaction mixture was washed four times, 
each time with 20 ml diethyl ether. After the complete removal of water by lyophilization, 
the crude product was dissolved in <10 ml CHCl3/CH3OH (2:1, v/v) and centrifuged at 
4,000 rpm for 20 min to remove the precipitate. 
In the third step, at room temperature, 1.6 mmol DCC was added to a solution of 
1.0 mmol oleic acid (Sigma-Aldrich Chemical Co.) in 10 ml anhydrous CHCl3 with 
stirring. The activation of the fatty acid was allowed to proceed for 30 min before adding 
0.3 mmol 13C=O (sn-1) lyso-PC from the second step and 0.1 mmol DMAP into the 
reaction mixture, which was then stirred at 37oC for 2 days. The reaction mixture was 
filtered and the filtrate, which contained the crude product, was added to a silica gel 
column. Product was eluted with a step gradient (sequential eluents: CHCl3; 
CH3OH/CHCl3, 15:85, v/v; CH3OH/CHCl3, 50:50, v/v).  
The product from each step was characterized and confirmed by 1H, 31P and 13C 
NMR and mass spectrometry. The final product was quantified by 31P by adding DOPMe 
as an external standard. 
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Figure A-1. Synthesis scheme for 13C=O (sn-1) labeled POPC. Abbreviations: GPC, 
sn-glycerol-3-phosphocholine. DCC, N,N’-dicyclohexylcarbodiimide. DMAP, 
4-(dimethylamino)pyridine. 
 
 
I.iii. Synthesis of 13C=O (sn-2) labeled phosphatidic acid and phosphatidylserine 
13C=O (sn-2) labeled phosphatidic acid (PA) and phosphatidylserine (PS) can be 
generated by PLD from the corresponding PC. 13C=O (sn-2) PC was prepared by 
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acylation of 1-palmitoyl-phosphatidylcholine with either [1-13C]-oleic acid or 
[1-13C]-palmitic acid as described previously (163). Briefly, at room temperature, 2.1 
mmol DCC was added to a solution of 1.0 mmol [1-13C]-oleic acid (Cambridge Isotope 
Laboratories, Inc.) in 10 ml anhydrous CHCl3 with stirring. The activation of the fatty 
acid was allowed to proceed for 30 min before adding 0.35 mmol 1-palmitoyl-2-
hydroxyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids, Inc.) in 5 ml anhydrous 
CHCl3 and 0.1 mmol DMAP into the reaction mixture, which was then stirred at 37
oC for 
22 h. The reaction mixture was filtered and the filtrate, which contained the crude product, 
was chromatographed on a silica gel column using the step gradient (sequential eluents: 
CHCl3; CH3OH/CHCl3, 15:85, v/v; CH3OH/CHCl3, 50:50, v/v). 
To generate 13C=O (sn-2) labeled phosphatidic acid (PA), 100 mg dried 13C=O 
(sn-2) POPC was hydrated in 12 ml buffer of 100 mM Tris, 10 mM CaCl2, pH 7.5 and 
sonicated to form SUVs. 2,500 units of PLD from Streptomyces chromofuscus (Enzo Life 
Sciences) was then added to the SUVs and stirred at 37oC for 24 h. 31P NMR indicated 
the conversion from PC to PA was complete. 1 ml 100 mM EGTA was added to the 
mixture to quench the reaction. After lyophilization, 5 ml water was added and pH 
readjusted to 7.5 (the pH was decreased to about 6.5 in the process of the reaction). The 
aqueous solution was extracted with 5 ml CH3OH/CHCl3 (2:1, v/v) three times. The 
organic extract was then washed with 2 ml 100 mM EGTA twice, followed by 2 ml water 
once. Finally, the removal of the organic solvent rendered the dried product. 
The conditions for generating 13C=O (sn-2) labeled phosphatidylserine (PS) from 
the corresponding PC were studied using unlabeled POPC. The reaction was carried out 
in a biphasic system. 50 mg dried POPC was mixed with 4 ml ethyl acetate and gently 
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sonicated on ice. To this cloudy mixture, 2 ml saturated L-serine solution (3.4 M in a 
buffer of 200 mM sodium acetate, pH 5.6), 40 mM CaCl2 and 1,000 units of PLC from 
Streptomyces sp. were added and stirred at 37oC for 24 h. Analysis of the reaction 
mixture using thin layer chromatography with a developing solvent system of 
choloroform:hexane:methanol:acetic acid (5:3:1.6:1, by volume) indicated that PC was 
completely converted to either PS or PA. The reaction was quenched with 1 ml 100 mM 
EGTA. After removing the solvent, 5 ml water was added and pH readjusted to 7.5. The 
aqueous solution was extracted with 5 ml CH3OH/CHCl3 (2:1, v/v) three times. The 
organic extract was then washed with 2 ml 100 mM EGTA twice, followed by 2 ml water 
once. The removal of the organic solvent rendered a dried mixture of PA and PS. They 
were separated on a CM-cellulose column using a step gradient (sequential eluents: 
CHCl3; CH3OH/CHCl3, 20:80, v/v; CH3OH/CHCl3, 50:50, v/v) (165). 
The products were characterized and confirmed by 1H, 31P and 13C NMR and 
mass spectrometry. It should be noted that in mass spectrometry, m/z calculated for 
POPS (C40H75NO10P [M – Na
+]) was 760.998, which should not be confused with POPC 
(C42H82NO8P, molecular weight 760.076). 
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